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Abstract 
 
Jamie K. Alan 
Tyrosine kinase modulation of trafficking and biological functions  
of the atypical Rho GTPase, Wrch-1. 
 
 (Under the direction of Dr. Adrienne D. Cox) 
 
Wrch-1 is an atypical Rho family small GTPase with roles in oncogenic transformation, 
epithelial cell morphogenesis, osteoclastogenesis, and migration. We have shown 
previously that Wrch-1 membrane localization and biological functions are modulated by 
reversible addition of a palmitate at its C-terminal membrane targeting domain. Most 
GTPases have at least two membrane targeting signals but no additional signals for 
Wrch-1 were known.  We now show that the subcellular localization of Wrch-1 is 
responsive to growth factors contained in serum and is modulated by Src-mediated 
tyrosine phosphorylation.  Upon stimulation with serum, Wrch-1 became phosphorylated 
on the evolutionarily conserved residue Y254 in its C-terminal membrane-targeting 
region, and relocalized from plasma membrane (PM) to endosomal compartments. 
Wrch-1 is known to interact with the adapter proteins Grb2 and Nck that in turn interact 
with growth factor receptor tyrosine kinases. We therefore next evaluated Wrch-1 
modulation by RTK ligands such as EGF or PDGF.  Wrch-1 was tyrosine phosphorylated 
in response to EGF treatment in time- and dose-dependent manner, and this was 
blocked by pretreatment with pharmacological inhibitors of either Src or EGFR.  Wrch-1 
relocalized rapidly from PM to endosomes upon EGF stimulation, similar to serum 
stimulation. Wrch-1 was phosphorylated at Y254 downstream of constitutively active 
forms of EGFR and HER2, including the deletion mutant EGFRvIII. Functionally, the 
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phosphodeficient Wrch-1 mutant Y254F was enhanced in Wrch-1-mediated migration, 
cystogenesis and transformation. Thus, EGFR, Src dependent, C-terminal tyrosine 
phosphorylation of Wrch-1 may represent a novel feedback mechanism to down-
regulate its activity. Consistent with this hypothesis, Wrch-1-GTP and effector activation 
are decreased after serum stimulated tyrosine phosphorylation and subsequent 
endosomal relocalization.  Also, we observed that phosphodeficient Wrch-1 remained 
GTP-bound and plasma membrane-localized in the presence or absence or serum, 
whereas a phosphomimetic mutant remained GDP-bound and localized at endosomes. 
Thus, EGFR-mediated, Src-dependent C-terminal tyrosine phosphorylation of Wrch-1 
may be a negative feedback mechanism to regulate both the trafficking and biological 
activities of Wrch-1.  C-terminal tyrosine phosphorylation represents a new paradigm in 
posttranslational control of small GTPase localization and biological function.    
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CHAPTER 1 
INTRODUCTION 
 
1.1 The Ras superfamily of small GTPases. The Ras (Rat sarcoma) superfamily of small 
GTPases consists of proteins that function to transmit intracellular signals initiated from 
extracellular stimuli (Figure 1.1A).  Ras small GTPases are involved in many divergent 
cellular functions including cytoskeletal reorganization, cell survival and proliferation, 
transformation and vesicular trafficking (Wennerberg et al., 2005) (Figure 1.1B).  These 
small GTPases function as tightly regulated molecular switches; when they are GTP-bound 
they undergo a conformational change, can engage effectors, and are active. Conversely, 
when they are GDP-bound, they cannot engage effectors and are inactive (Figure 1.2A).  
Two types of proteins regulate the GDP/GTP cycle of these small GTPases. Guanine 
nucleotide exchange factors (GEFs) are positive modulators; they function to exchange 
GDP for GTP and consequently they activate small GTPases. GTPase accelerating proteins 
(GAPs) work by hydrolyzing the terminal phosphate of GTP, leaving the protein GDP-bound 
and inactive (Figure 1.2A).  Oncogenically activating mutations that occur in cancer render 
GTPases GAP-insensitive, and therefore constitutively GTP-bound and active (Figure 1.2B).  
In Ras, these mutations typically occur at position 12, 13 or 61 (Figure 1.2C). These 
mutations can also be utilized in the laboratory to study GTPase function. The Ras 
superfamily is divided into 5 main subfamilies: Ras, Rho, Rab, Arf and Ran. Ras subfamily 
proteins are well known for their role in driving cell proliferation.  The Rho subfamily of 
proteins are primarily known for regulating cytoskeletal dynamics. The Arf and Rab families 
of proteins regulate vesicular transport, whereas the Ran GTPase primarily regulates 
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nuclear transport (Wennerberg et al., 2005). 
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Figure 1.1  The Ras superfamily of small GTPases.  A)  The Ras superfamily consists of 
five branches (modified from Wennerberg and Der, 2004).  B) Ras family GTPases 
mediate diverse downstream biological functions.  
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Figure 1.2  Small GTPases are regulated by GDP/GTP binding.  A)  GEFs  
promote GTP binding, resulting in an activated GTPase. GAPs hydrolyze GTP, 
leaving the proteins GDP-bound and inactive.  B) When GTPases can cycle 
between the GDP and GTP state, they promote normal biological outcomes. 
When they are constitutively GTP-bound, they promote oncogenic outcomes.  C) 
There are naturally occurring and synthetic mutations in GTPases that render 
then GTP-bound and constitutively active. 
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1.2 The Rho family of small GTPases.  The Rho family of GTPases comprises a major 
subgroup of the Ras superfamily of small GTPases. Structurally, Rho GTPases are defined 
by a Rho insert domain between the fifth β strand and the fourth α helix in the GTPase 
domain. Rho family members are best known for their ability to control the actin cytoskeleton 
by regulating structures such as actin stress fibers, lamellipodia, and filopodia (Wennerberg 
and Der, 2004; Wherlock and Mellor, 2002).  Within the Rho family, the core GTPase 
domain contains a Rho insert domain is highly conserved between family members, 
whereas they are divergent in their N-terminal extensions and in their C-terminal 
hypervariable regions.  In humans there are 23 members of the Rho family, which are 
divided into 5 major families: Rho, Rac (Ras-related C3 substrate), Cdc42 (cell division cycle 
42), Rnd (round), and RhoBTB (Rho Broad-Complex, Tramtrack and Bric à brac) (Figure 
1.3).  The best-studied members are RhoA, Rac1, and Cdc42. The Rho and Rac subgroups 
are best known for their roles in cytoskeletal rearrangement, driving formation of actin stress 
fibers and lamellipodia, respectively. Cdc42 family members are also involved in regulating 
the actin cytoskeleton by inducing filopodia formation, but additionally they play a major role 
in controlling cell polarity.  The Rnd subgroup of Rho GTPases also plays an important role 
in controlling the actin cytoskeleton (Nobes et al., 1998), and Rnd3 has also been shown to 
be important in cell-cycle progression and transformation (Hansen et al., 2000; Villalonga et 
al., 2004).  Although less is known about the other family members, RhoBTB and Miro 
proteins are being investigated for their potentially distinct roles in actin cytoskeleton control, 
oncogenesis, and mitochondrial functions (Aspenstrom et al., 2004; Fransson et al., 2003; 
Wennerberg and Der, 2004). 
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Figure 1.3  The Rho family of small GTPases.  The Rho family of small GTPases 
contains 23 members, 20 of which are shown here. The three best studied are RhoA, 
Rac1, and Cdc42. Wrch-1 is a member of the Cdc42 subfamily of small GTPases. 
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Figure 1.4  Rho GDIs regulate Rho GTPases.  Rho GDIs function by inhibiting 
GDP dissociation and by sequestering Rho GTPases in the cytosol. 
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Like Ras small GTPases, Rho GTPases also function as molecular switches that cycle 
between a GTP-bound active state and a GDP-bound inactive state. Rho proteins are also 
modulated by GEFs, which exchange GDP for GTP, and GAPs which hydrolyze the terminal 
phosphate of GTP, rendering the protein GDP-bound. The first RhoGEF was isolated from a 
gene that was transforming in human diffuse B-lymphoma cells (Dbl) (Eva et al., 1988; Ron 
et al., 1988).  Dbl is now known to be an exchange factor for Cdc42 (Hart et al., 1991). The 
domain in Dbl responsible for exchange was subsequently found in many other RhoGEFs 
and was termed the Dbl-homology (DH) domain.  DH domain-containing GEFs are found in 
many organisms, H. sapiens D. melanogaster, C. elegans, and S. cerevisiae to name a few.   
DH domain-containing RhoGEFs also contain a pleckstrin homology (PH) domain, which is 
usually immediately adjacent and C-terminal to the DH domain (Rossman et al., 2005).  
Usually, both the DH and PH domain are minimally required to catalyze the exchange of 
GDP for GTP.  RhoGEFs work by promoting the dissociation of GDP, the stabilizing Mg2+ 
ion, and promoting a nucleotide-free intermediate. (Cherfils and Chardin, 1999).  Because of 
the high concentration of GTP relative to GDP in the cell, after GDP is released, GTP can 
replace GDP in the nucleotide-binding region of the small GTPase. Remarkably, the number 
of RhoGEFs outnumber target GTPases by a factor of 3, which suggests that multiple GEFs 
can be capable of activating the same GTPase (Rossman et al., 2005; Schmidt and Hall, 
2002). For example, it is known that the RhoGEF Trio is capable of activating both Rac1 and 
RhoG in mammalian cells (Blangy et al., 2000). However, some GEFs are specific for a 
particular Rho GTPase. For example, p115RhoGEF activates RhoA exclusively (Kozasa et 
al., 1998).  In general, RhoGEFs are regulated by their negative regulatory N-terminus; the 
N-terminus sterically blocks the DH domain, and prevents exchange activity.  
Phosphorylation of some RhoGEFs relieves the N-terminus/DH domain interaction, allowing 
the GEFs to become active.   Vav2 is a well-characterized example of a RhoGEF that is 
regulated by phosphorylation.  Phosphorylation of Vav2 by tyrosine kinases such as Lck 
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(Han et al., 1997) relieves the N-terminal inhibition of Vav2, opening up  the DH domain, 
which can then interact with Rho GTPases (Aghazadeh et al., 2000; Crespo et al., 1997). 
 
As previously mentioned, Rho proteins are also negatively regulated by RhoGAPs.  Rho 
proteins contain an intrinsic ability to hydrolyze GTP to GDP, however this process is very 
slow, unless catalyzed by a GAP.  Classically, RhoGAPs contain an "arginine finger" that is 
the catalytically active subunit of the GAP. This "arginine finger" functions to accelerate the 
hydrolysis of GTP to GDP by stabilizing the transition state of the substrate-binding site of 
the small GTPase (Rittinger et al., 1997).   There are currently approximately 170 proteins 
that are predicted to possess GAP activity against various members of the Ras superfamily 
and about 70 of these proteins contain a predicted Rho/Rac GAP domain (Lander et al., 
2001).  In vitro, many of the GAPs that contain the Rho/Rac GAP domain interact with 
several members of the Rho subfamily of small GTPases; however, some GAPs are specific 
to a particular Rho GTPase. For example, p50RhoGAP can regulate RhoA, Rac1 (Lancaster 
et al., 1994), and Cdc42 (Barfod et al., 1993), whereas p190RhoGAP (Ridley et al., 1993) 
and RhoGAP6 (Prakash et al., 2000) are both specific for Rho.   In addition to the GAP 
domain, RhoGAPs also contain many putative protein and lipid interaction motifs that can 
modify the localization, activity and/or substrate specificity of these proteins (Ligeti et al., 
2004).  
 
As a third level of regulation, in addition to GEFs and GAPs, Rho proteins are also regulated 
by guanine nucleotide dissociation inhibitors (GDIs).  Three human RhoGDIs have been 
identified: RhoGDI-1/RhoGDI-α, which is ubiquitously expressed (Ueda et al., 1990), 
RhoGDI-2/RhoGDI-β, which is expressed in hematopoietic cells (Lelias et al., 1993; Scherle 
et al., 1993), and RhoGDI-3/RhoGDI-γ, which is expressed only in lung, brain, and testes 
(Adra et al., 1997; Zalcman et al., 1996).  GDIs inhibit Rho proteins in two ways: they inhibit 
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GDP dissociation and also sequester Rho proteins in the cytosol, rendering them inactive 
(DerMardirossian and Bokoch, 2005) (Figure 1.4). When GDIs bind to Rho proteins, they 
interact with the effector-binding domain with high affinity (low nanomolar range 
(Nomanbhoy, 1996 #313)), which is comparable to or better than the affinity for the GTPase 
for most effectors (Nomanbhoy et al., 1999).  Additionally, RhoGDIs have a hydrophobic 
pocket that can accommodate the geranylgeranyl or farnesyl groups attached to the CAAX 
boxes of most Rho family proteins (Hoffman et al., 2000). 
 
In addition to regulation by GEFs, GAPs, and GDIs, Rho proteins are regulated by their 
subcellular localization.  Typically Rho proteins are modified by the irreversible addition of a 
prenyl group to a C-terminal CAAX motif (Adamson et al., 1992; Casey and Seabra, 1996).   
These isoprenoid lipids are either a C15 farnesyl group or a C20 geranylgeranyl group 
(Figure 1.5A).  It is important to note that canonical CAAX motifs are not present in Wrch-1, 
Chp/Wrch-2, RhoBTB1, or RhoBTB2 (Roberts et al., 2008).  These lipids are added by the 
enzymes, farnesyltransferase (FTase) or geranylgeranyltransferase I (GGTase I), 
respectively.  Following the addition of an isoprenoid group to the C-terminal cysteine, the 
AAX group is proteolytically cleaved by a CAAX-specific protease, Rce1 (Boyartchuk et al., 
1997; Kim et al., 1999; Winter-Vann and Casey, 2005).  Subsequently, the prenylated 
cysteine is then methylated by isoprenylcysteine carboxyl methyltransferase (ICMT) (Clarke 
et al., 1988; Winter-Vann and Casey, 2005) (Figure 1.5B).  After the completion of these 
steps, the post-translationally processed Rho protein translocates from the cytosol to the 
plasma membrane (Figure 1.5B).  Studies have shown that a cysteine to serine mutation in 
the CAAX motif (CAAX>SAAX), which render the proteins unprenylated, results in 
mislocalization of Rho proteins to the cytosol, resulting in their inactivity (Winter-Vann and 
Casey, 2005).  For example, mutation of RhoA CLVL>SLVL and RhoB CKVL>SKVL causes 
cytosolic mislocalization of these proteins (Adamson et al., 1992). Similarly, a C>S mutation 
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in Rac1 (CLLL>SLLL), renders it insensitive to GGTase I modification, and results in a 
mislocalization of Rac1 (Joyce and Cox, 2003).  Furthermore, isoprenylation alone is not 
sufficient to correctly target many Rho GTPases to their correct subcellular localization.  
Proper posttranslational processing by both Rce1 and ICMT are both required for correct 
localization of many Rho GTPases (Roberts et al., 2008).  Rce1 activity is required for 
proper localization of RhoB, Rnd1, Rnd2, Rnd3, TC10, TCL, RhoD, Rif and RhoH (Roberts 
et al., 2008). ICMT activity is required for proper localization of RhoA, Rnd1, Rnd2, Rnd3, 
TC10, TCL, Rif, and RhoH (Roberts et al., 2008).  In addition to the prenyl group attached to 
the C-terminal CAAX motif, Rho proteins are typically modified by a "second signal" 
upstream of the prenyl modification.  This "second signal" is required for proper plasma 
membrane localization.  There are two classic "second signals" that have been described 
and characterized, first for Ras proteins, and then for Rho proteins: the addition of a 
palmitate fatty acid, or the presence of a polybasic region upstream of the prenylation site 
(Hancock et al., 1990) (Figure 1.6).  For example, both RhoB and TC10 require a palmitoyl 
modification upstream of the isoprenyl group for proper localization (Michaelson et al., 
2001), whereas Cdc42 relies on an upstream polybasic region (Williams, 2003). There is 
data to show that "second signals" in the hypervariable domains can drive Rho proteins to 
distinct subcellular compartments.  RhoB, which is palmitoylated, is targeted to internal 
membranes, Golgi, and peri-Golgi vesicles (Michaelson et al., 2001). TC10, which 
incorporates both a palmitoylation site and a polybasic region, localizes to both the plasma 
membrane and internal membranes (Michaelson et al., 2001).  Rac1, which has a strong 
polybasic region, localizes primarily to the plasma membrane. In contrast, both Cdc42 and 
Rac2, which both have a weak polybasic region when compared to Rac1, localize primarily 
to internal membranes, with a small proportion of the protein localizing to the plasma 
membrane (Michaelson et al., 2001). Additionally, other additional flanking sequences in the 
hypervariable domain in Ras have been shown to be important for proper localization 
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(Willumsen et al., 1996). Additional posttranslational modifications, such as phosphorylation, 
can also modulate the localization of small GTPases, and this is the major focus of my 
dissertation.   
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Figure 1.5 Rho proteins are modified post-translationally with isoprenoid lipids. A) 
Either a C15 farnesyl or a C20 geranylgeranyl group can be added to Rho proteins. B) 
Post-prenyl processing:  after isoprenylation of the CAAX motif, Rho GTPases are 
further processed by Rce1 and ICMT. 
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Figure 1.6 A second signal is required for proper Rho protein membrane localization. 
Second signals are typically comprised of either a palmitate fatty acid or a polybasic 
region upstream of the C-terminal CAAX motif. 
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Figure 1.7 Cdc42- family members share sequence similarities. 
The Cdc42 subfamily of small GTPases has 5 members that are most similar within their 
GTP-binding region, effector domain, and Rho insert region. Divergent sequences and 
modifications within their C-terminal hypervariable regions and CAAX motifs dictate 
different localization and function. 
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1.3 The Cdc42 subfamily of Rho GTPases.  Cdc42 is the founding and most well studied 
member of the Cdc42 subfamily.  Cdc42 was originally identified in yeast where it functions 
as a regulator of cell polarity and cellular division (Ziman et al., 1993).  In mammalian cells, 
Cdc42 regulates cytoskeletal organization, especially filopodial structures.  Additionally, 
roles for Cdc42 have been defined in normal cell growth and polarity, gene expression, cell 
cycle progression, and in tumorigenesis when aberrantly regulated (Aspenstrom et al., 2004; 
Wennerberg and Der, 2004). The Cdc42 subfamily of small GTPases consists of 5 proteins: 
Cdc42, TC10 (teratocarcinoma 10), TCL (TC10-like) and the Wrch proteins, Wrch-1 (Wnt- 
regulated Cdc42 homolog-1) and Chp (Cdc42 homologous protein)/Wrch-2.  These proteins 
share high sequence identity within the GTP- and effector-binding regions, and differ the 
most in their N- and C-terminal extensions (Figure 1.7).  As with all small GTPases, the 
GTPase domain undergoes a conformational switch when it is GTP-bound, allowing these 
proteins to interact with effectors through the effector-binding domain.  Because the Cdc42 
subfamily shares high sequence similarity within the effector-binding domain, it is easy to 
think that these proteins utilize similar effectors to elicit biological function and are therefore 
redundant.  However, the presence of unique sequence elements within the effector-binding 
domain, and divergent hypervariable regions (important for localization) within the subfamily 
confer enough divergence to promote unique functions within the Cdc42 subfamily.  Most 
Cdc42 effectors contain the Cdc42/Rac-interactive binding (CRIB) domain that is required 
for interactions with the effector-binding domain of Cdc42 (Cotteret and Chernoff, 2002).  
Exceptions to this include phosphotidylinositol 3-kinase (PI3K), CIP4 and IQGAP, which 
interact with a region in the effector domain that is distinct from the region that interacts with 
the CRIB domains (Bishop and Hall, 2000; Cotteret and Chernoff, 2002).  One of the major 
effectors of Cdc42 is the serine/threonine kinase, p21-activated kinase (PAK), which binds 
through its CRIB domain to Cdc42.   When Cdc42 is GTP-bound, it can then bind and 
activate PAK by stimulating autophosphorylation of the kinase (Manser et al., 1994; Martin 
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et al., 1995).  PAK activity downstream of Cdc42 has been shown to be important in many 
Cdc42-driven biological activities, including transformation, morphogenesis and cell cycle 
progression.     
 
Cdc42 and related proteins reduce stress fibers and focal adhesions, and promote the 
formation of filopodia.  These cytoskeletal changes are thought to be induced by signaling 
through PAK as well as other Cdc42 effectors.  Another major class of Cdc42 effectors 
includes the Wiskott-Aldrich syndrome protein (WASP) family members, which bind through 
their CRIB domains to Cdc42 (Li et al., 1999).   Downstream of Cdc42, WASP proteins 
facilitate the formation of filopodia.   Cdc42 also controls epithelial cell polarity, which is 
mediated by the formation of distinct apical and basolateral membrane regions, which are 
separated by tight junctions.  Establishment of polarity is required for directional movement 
of cells, and if polarity is disrupted it can contribute to more motile and invasive phenotypes.  
Cdc42 controls tight junction formation by its interactions with two proteins; partitioning 
defective 6 (Par6) and atypical protein kinase Cs (aPKCs).  This dissertation will focus on 
Wrch-1 (Wnt-regulated Cdc42 homolog-1), a more recent addition to the Cdc42 subgroup.  
Wrch-1 shares some effectors with Cdc42 to elicit its cellular effects, and but also utilizes 
other effectors, that are not associated with Cdc42.  
 
Like Cdc42, Wrch-1 can bind to and stimulate autophosphorylation of PAK1 (Tao et al., 
2001) and, as discussed later in this dissertation, activation of PAK1 by Wrch-1 is regulated 
by Wrch-1 phosphorylation status.  Wrch-1 also binds to the Par6 and PKCζ complex (Saras 
et al., 2004) to control epithelial cell morphogenesis (Brady et al., 2009).  Unlike Cdc42, 
Wrch-1 does not bind to WASP family proteins such as CIP4 or Spec1, as shown by a yeast 
2-hybrid analysis (Aspenstrom et al., 2004).   Taken together, this information suggests that 
Wrch-1 possesses some similarities to Cdc42 in terms of effector binding, but also is 
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divergent from Cdc42 because it can utilize different effectors. 
 
1.4 Wrch-1, an atypical Rho family member.     Wrch-1 (Wnt-regulated Cdc42 homolog-
1) and Chp/Wrch-2 (Cdc42-homologous protein), the most recently identified Rho family 
members, share 57% and 52% sequence identity with Cdc42, respectively, and 61% 
sequence identity with each other (Aronheim et al., 1998; Tao et al., 2001).  Canonical Rho 
GTPases include RhoA, RhoB, RhoC, Rac1, Rac2, Rac3, and Cdc42.  These members of 
the Rho family of small GTPases are considered canonical because they are tightly 
regulated by GDP/GTP-binding, through regulation by GEFs, GAPs, and GDIs.  Additionally, 
they undergo typical post-translational modifications, such as an isoprenyl group on their C-
terminal CAAX motif, and an additional second signal such as a polybasic region or an 
upstream palmitate, which will be discussed in more detail below.  Atypical Rho proteins 
vary in either their regulation of GTP/GDP-binding, the presence of other domains besides a 
Rho insert domain, and variances in their N- and C-termini and/or posttranslational 
modifications.  For example, the Rnd subfamily of proteins are constitutively GTPase-
deficient and they are not stable in either a GDP-bound or a nucleotide-free form (Nobes et 
al., 1998).   Rnd3, also known as RhoE and Rho8, is constitutively GTP-bound in vivo 
(Foster, 1996 #4;Nobes, 1998 #231).  RhoD and Rif contain additional N-terminal 
sequences when compared to the canonical Rho GTPases (Ellis and Mellor, 2000; Murphy 
et al., 1996). RhoH, also known as TTF (translocated three four), is expressed specifically in 
hematopoietic cells (Dallery et al., 1995), and plays a role in both non-Hodgkins lymphoma 
and multiple myeloma (Preudhomme et al., 2000).  In RhoH, similar to the Rnd proteins, the 
residues analogous to G12 and Q61 in other Rho proteins are not conserved, and RhoH is 
likely to also be GTPase-deficient (Li et al., 2002).  When compared to the other members of 
the Cdc42 family, Wrch-1 has elongated N-terminal and C-terminal extensions (Figure 1.8).  
The N-terminus has been shown to be an auto-inhibitory domain: removal of the N-terminus 
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increases biological activity (Berzat et al., 2005b; Shutes et al., 2006; Shutes et al., 2004). 
The N-termini of both Wrch-1 and Chp contain PxxP motifs, which may mediate interactions 
with proteins containing SH3 domains, such as the adaptor proteins Grb2 and Nck.  The 
RhoBTB family consists of three proteins in humans: RhoBTB1, RhoBTB2, and RhoBTB3. 
The RhoBTB subfamily proteins are also structurally different from the canonical Rho 
GTPases, in that they contain a tandem repeat of BTB subdomains and lack C-terminal 
CAAX motifs  (Ramos et al., 2002).  Additionally, their GTPase domains are altered when 
compared to the canonical Rho GTPases.  RhoBTB1 and 2 contains a Rho insert domain 
that is longer than usual, contains many charged residues, and also contains insertions and 
deletions in the GTPase domain.  One of the deleted residues is analogous to Q61 in Ras, 
and also the G12 position is substituted by an asparagine in RhoBTB1 and 2.  These 
proteins would be predicted to display impaired enzyme activity. Consistent with this 
hypothesis, in vitro RhoBTB2 does not bind GTP (Chang et al., 2006).  Furthermore, 
RhoBTB3 has an extremely truncated GTPase domain, to the point where it is almost 
unrecognizable as a GTPase domain, and does not bind GTP (Berthold et al., 2008) but 
instead is an ATPase (Espinosa et al., 2009). However, like canonical Rho GTPases, 
RhoBTB3 does have a prenylation motif, and is farnesylated (Berthold et al., 2008).  Finally, 
the Miro subfamily contains not only one, but two Rho GTPase domains (the N-terminal Rho 
GTPase domain is most similar to other Rho GTPase domains) and two EF-hand motifs 
(Fransson et al., 2003).  
 
 Wrch-1 is also divergent in the C-terminus, when compared to other members of the Cdc42 
family.  Like Chp (Chenette et al., 2006), instead of being irreversibly prenylated on a CAAX 
motif, Wrch-1 is reversibly palmitoylated on a CFV motif (Berzat et al., 2005b) (Figure 1.9). 
Although palmitoylation as a primary lipid modification has not been described for Rho 
GTPases other than Chp or Wrch-1, there are several proteins in Arabidopsis and maize,  
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that terminate in CXX motifs, and their localization and function depend on the addition of a 
palmitate fatty acid, rather than a prenyl group, on this motif (Ivanchenko et al., 2000; Lavy 
et al., 2002).  There are eleven Rho-related proteins in Arabidopsis, typically referred to as 
Rops (Rho in plants) (Zheng and Yang, 2000) or RACs (Winge et al., 2000). Of the eleven 
Rho proteins in Arabidopsis, eight are prenylated on CAAX motifs and three rely on 
palmitoylation of a CXX motif for association with plasma membrane and proper elongation 
of the root hair (Lavy et al., 2002). Additionally, there are two ROP proteins in maize, both of 
which terminate in CXX motifs (Ivanchenko et al., 2000), similar to those found in 
Arabidopsis, and also similar to Wrch-1 and Chp in humans.   
 
The palmitoylation/depalmitoylation of proteins is a rapid and reversible cycle that utilizes 
specific protein S-acyltransferases (PATs) for transfer of palmitoyl fatty acids onto cysteines, 
and palmitoyl protein thioesterases (PPTs) for removal of the palmitates (Resh, 1999).  
Although protein palmitoylation was discovered more than 20 years ago, the enzymes 
responsible for this modification have only been recently described (Linder and Deschenes, 
2003; Linder and Deschenes, 2004; Lobo et al., 2002; Roth et al., 2002) and their identities 
and modes of action are still under active exploration.   Although the addition of a palmitate 
can occur spontaneously in vitro (Bharadwaj and Bizzozero, 1995; Duncan and Gilman, 
1996; Quesnel and Silvius, 1994), two classes of protein palmitoylating enzymes have been 
discovered (Lobo et al., 2002; Roth et al., 2002).   Members of the first class of PATs share 
a DHHC domain, which is a cysteine-rich domain with a conserved Asp-His-His-Cis motif, 
suggested to be the domain responsible for palmitoyl transfer (Roth et al., 2002). Examples 
of proteins that contain the DHHC domain are Erf2/Erf4 in yeast, which have been shown to 
palmitoylate Ras, and Akr1 which is the related PAT for yeast casein kinase II.  Members of 
the second class of PATs act on proteins in the lumen of the secretory pathway (Chamoun 
et al., 2001; Miura et al., 2006; Zhai et al., 2004).  In D. melanogaster, there is evidence that 
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skinny hedgehog (also called Rasp, Central missing, and Sightless) is required for 
palmitoylation of Hedgehog (Chamoun et al., 2001) and Spitz (Miura et al., 2006).   
Additionally, another D. melanogaster protein, porcupine, is required for palmitoylation of 
Wnt proteins (Zhai et al., 2004). 
 
Palmitoyl protein thioesterases (PPTs) are required for the removal of palmitoyl 
modifications. Although no direct work has been done to demonstrate the activity of PPTs 
on Rho proteins, pulse-chase experiments were first done to demonstrate the turnover of 
palmitate on H- and N-Ras (Magee et al., 1987), the transferrin receptor (Jing and 
Trowbridge, 1987), and ankyrin (Staufenbiel, 1987), to name a few. Additionally, it has been 
shown that there is a requirement for Ras to be in the native conformation, along with a 
requirement for the presence of Mg2+ for  PPT1 to remove the palmitate from H-Ras (Camp 
and Hofmann, 1993).  Other in vitro work has shown that PPT1 and acyl protein thioestrase 
(APT1) can both remove palmitate modifications from Ras proteins (Duncan and Gilman, 
1998).  Importantly, the palmitoylation/depalmitoylation cycle has been shown to be dynamic 
and reversible (Rocks et al., 2005; Zhang and Rock, 2008), and may serve as a dynamic 
mechanism to regulate small GTPase localization and function.  In support of this notion, 
palmitoylation is required for proper membrane localization and biological function of Wrch-1 
(Berzat et al., 2005b).  A mutant that cannot be palmitoylated (Wrch-1 SSFV) is mislocalized 
and causes a decrease in anchorage-independent growth (Berzat et al., 2005b).  As 
mentioned before, many Rho proteins utilize a "second signal", such as an upstream 
palmitate or poly-basic region to properly regulate their localization to the plasma 
membrane.  Currently, there is no known "second signal" for Wrch-1 plasma membrane 
localization; there is no identifiable polybasic region, and there is no upstream cysteine 
available in the C-terminus for palmitoylation. 
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Wrch-1 was initially discovered as a Wnt-responsive gene, whose expression (measured by 
mRNA) was increased in response to Wnt-1 signaling in Wnt-1-transformed cells, Wnt-1-
transgene-induced mouse mammary tumors, and Wnt-1 retrovirus-infected cells (Taneyhill 
and Pennica, 2004; Tao et al., 2001).  When Wrch-1 is mutationally activated (Q107L, 
analogous to a Ras Q61L mutation) it phenocopied Wnt-1-mediated morphological 
transformation of mammary cells (Tao et al., 2001).  The Wnt family of secreted proteins are 
critical mediators of cell-cell signaling in development.  The first Wnt gene, Wnt1, was 
discovered as a proto-oncogene that was activated by integration of a mouse mammary 
tumor virus into mammary cells.  Wnt proteins have been extensively characterized in D. 
melanogaster and C. elegans. When cells are not exposed to Wnt, β-catenin is degraded 
through interactions with Axin, APC and GSK-3. When Wnt ligands interact with the 
transmembrane receptor Frizzled they work by inhibiting the Axin/APC/GSK-3 complex to 
induce elevation of cytoplasmic β-catenin, which can then interact with TCF to control 
transcription (Klingensmith and Nusse, 1994; Klingensmith et al., 1994; Peifer et al., 1994; 
Siegfried et al., 1994; Theisen et al., 1994; Zeng et al., 1997).   Normally Wnt signaling is 
present in the developing organism, and is in place to promote normal development.  
However in adults, mis-regulation of the Wnt signaling pathway can lead to a variety of 
abnormalities and disease.  Therefore, regulation of Wrch-1 in response to Wnt simulation 
could be hypothesized to mediate both normal development, and disease driven by aberrant 
Wnt signaling in adults.     
 
Chp/Wrch-2, a protein highly related to Wrch-1, was identified in a screen that was designed 
to look for proteins that interact with p21-activated kinase (Pak1) (Aronheim et al., 1998).  
Both Wrch-1 and Chp/Wrch-2 are expressed ubiquitously at very low levels, with a higher 
level of expression in the brain and placental tissue (Aronheim et al., 1998; Tao et al., 2001).  
Interestingly, Wrch-1 and Chp are both important in chicken embryonic development, 
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however they are expressed in different spatial and temporal patters during chick 
embryogenesis, suggesting distinct roles in this process (Notarnicola, 2008 #434).  Like 
Wrch-1, Chp also contains N- and C-terminal extensions when compared to Cdc42. The N-
terminus of both Wrch-1 and Chp functions as an auto-inhibitory domain (Chenette et al., 
2005; Shutes et al., 2004).  When the N-terminus of either Wrch-1 or Chp is deleted, both 
proteins display enhanced biological functions such as increased transformation (Chenette 
et al., 2005; Shutes et al., 2004). Additionally, both Wrch-1 and Chp terminate in a CFV 
motif, and both are palmitoylated on the cysteine of this motif (Berzat et al., 2005b; Chenette 
et al., 2005), a modification that is necessary for their membrane association and function 
(Berzat et al., 2005b; Chenette et al., 2005). Because both Wrch-1 and Chp are 
palmitoylated instead of being prenylated, neither protein interacts with RhoGDIs (Berzat et 
al., 2005b; Chenette et al., 2006).  Unlike Wrch-1, but similar to Cdc42, Chp requires the 
presence of a stretch of basic amino acids in the C-terminal membrane-targeting motif 
(Chenette et al., 2006). Chp also requires the presence of a conserved tryptophan in the C-
terminal membrane-targeting region (Chenette et al., 2006), and although Wrch-1 
possesses a tryptophan residue in the 9aa minimal targeting sequence (Berzat et al., 
2005b), it has not been determined whether this residue is important for proper localization 
of full-length Wrch-1.   Interestingly, Chp has been shown to be activated at internal 
membranes in response to stimulation by TNFα (Chenette et al., 2006), by a yet-
undetermined mechanism; however, Wrch-1 activation in response to TNFα has not been 
examined. 
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Figure 1.8 Wrch-1 contains a GTPase domain, Rho insert domain, and effector domain 
similar to those of Cdc42. However, unlike Cdc42, Wrch-1 also contains an N-terminal 
extension containing polyproline motifs and a C-terminal extension that is modified with 
a palmitate fatty acid instead of a geranylgeranyl isoprenoid lipid. 
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Figure 1.9 Wrch-1 utilizes a palmitate fatty acid added to its CFV motif, rather 
than an isoprenoid lipid on a CAAX motif, for proper membrane localization and 
activity 
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Figure 1.10 Wrch-1 is evolutionarily conserved.  Wrch-1 homologues are expressed in 
many organisms from sea squirts to humans. Interestingly, there is no Wrch-1 
equivalent in fruit flies, a commonly used model organism. Note that the critical 
residue, Y254, whose regulatable modification by phosphorylation is the key subject of 
this dissertation, is evolutionarily conserved (red Y). 
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Wrch-1 homologs or orthologs have been found in many organisms, including human, 
mouse, dog, chicken, zebrafish, sea squirt and trematodes, demonstrating evolutionary 
conservation of Wrch-1 (Figure 1.9).  Interestingly Wrch-1 is not found in some other 
important model organisms, such as fruit flies, however there is a Wrch-1/Chp hybrid found 
in C. elegans, named Chw-1.  Currently there are no identified GEFs, GAPs, or GDIs known 
to interact with and regulate Wrch-1.   In vitro, Wrch-1 has a very high rate of GDP/GTP 
exchange, suggesting that Wrch-1 may be constitutively GTP-bound in cells (Shutes et al., 
2006). However, a putative dominant negative of Wrch-1, T63N, does not behave like wild 
type (Ruusala and Aspenstrom, 2008), supporting the idea that at least one GEF may still 
be important to activate Wrch-1.  In addition, in biological assays, a GTPase-insensitive 
mutant of Wrch-1 (Q107L) shows significantly higher activity than wild-type Wrch-1 (Berzat 
et al., 2005b; Brady et al., 2009; Brazier et al., 2009; Chuang et al., 2007; Ory et al., 2007; 
Ruusala and Aspenstrom, 2008; Saras et al., 2004), suggesting that there is at least one 
GAP that inactivates Wrch-1 which has yet to be identified. 
 
Although Wrch-1 is a fairly recent addition to the Cdc42 subfamily, several effectors have 
been identified.  Wrch-1 shares some of the same effectors as Cdc42, including PAK1 and 
the Par6/PKCζ polarity complex (Brady et al., 2009; Saras et al., 2004; Tao et al., 2001). 
Wrch-1 also has effectors that it does not share with Cdc42, including the non-receptor 
tyrosine kinase Pyk2 (Ruusala and Aspenstrom, 2008).  Several important biological 
functions have been ascribed to Wrch-1 including regulation of the actin cytoskeleton (Brady 
et al., 2009; Ruusala and Aspenstrom, 2008; Saras et al., 2004; Tao et al., 2001), 
anchorage-independent growth (Berzat et al., 2005b; Brady et al., 2009), focal adhesion 
formation (Chuang et al., 2007 Ory, 2007 #124), cell migration (Brazier et al., 2009; Chuang 
et al., 2007; Ory et al., 2007), osteoclastogenesis (Brazier et al., 2009; Ory et al., 2007) and 
epithelial cell morphogenesis (Brady, 2009 #15).  Originally, Wrch-1 was discovered in a 
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screen designed to identify genes that were up-regulated in a murine mammary epithelial 
cells that stably express Wnt1 (Tao et al., 2001). In the same study, Wrch-1 was found to 
activate both PAK-1 and C-Jun using in vitro kinase assays (Tao et al., 2001).  Wrch-1 also 
induced filopodia formation and stress fiber dissolution in Swiss 3T3 cells, and also 
stimulated these cells to re-enter the cell cycle (Tao et al., 2001). Expression of 
constitutively activated Wrch-1 caused morphological transformation of mouse mammary 
epithelial cells, similar to Wnt-mediated morphological transformation (Taneyhill and 
Pennica, 2004; Tao et al., 2001).  Taken together, this data suggested that Wrch-1 may be 
important in Wnt-mediated transformation of cells.  
 
Wrch-1 was also identified in another screen designed to identify mRNA that was 
upregulated during the differentiation of macrophages into osteoclasts (Brazier et al., 2006).  
Following this observation, Wrch-1 was shown to localize to the podosome belt and is 
associated with Src-induced podosomes in osteoclasts (Ory et al., 2007). Wrch-1 was also 
shown to localize to focal adhesions, where it reduces overall adherence (Brazier et al., 
2009) and the number of focal adhesions in osteoclasts (Ory et al., 2007) and HeLa cells 
(Chuang et al., 2007).  Because focal adhesions and podosomes are important structures in 
migration and invasion respectively, it was thought that Wrch-1 activity within these 
structures may regulate migration and/or invasion.  Indeed, Wrch-1 overexpression 
increased migration in both osteoclasts and HeLa cells (Brazier et al., 2009; Chuang et al., 
2007; Ory et al., 2007).  Conversely, Wrch-1 depletion led to an increase in focal adhesions, 
by regulating myosin light chain, and a decrease in migration (Chuang et al., 2007). Wrch-1 
mediated migration is thought to be accomplished through activation of Akt and JNK 
because Wrch-1 is necessary for wound-healing mediated by Akt and JNK activation 
(Chuang et al., 2007).  
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Wrch-1 expression reduced osteoclast adhesion onto vitronectin but not fibronectin and also 
increased osteoclast precursor aggregation (Brazier et al., 2009).  Increased aggregation 
and decreased adhesion in osteoclasts was mediated through Wrch-1 binding to the 
cytoplasmic domain of integrin β3, and interference with adhesion induced Pyk2 and paxillin 
phosphorylation (Brazier et al., 2009).  Wrch-1 also binds to Pyk2 in PAE/PDGFRβ cells, 
where activation of Wrch-1 results in increased Pyk2 phosphorylation and activation 
(Ruusala and Aspenstrom, 2008).  In these cells, Wrch-1 requires both Pyk2 and Src 
expression and activity for the formation of filopodia (Ruusala and Aspenstrom, 2008). 
 
Wrch-1 has also been shown to promote anchorage-independent growth in several cell 
types (Berzat et al., 2005b; Brady et al., 2009).  Wrch-1-mediated anchorage-independent 
growth is dependent on the presence of a palmitate fatty acid on its CFV motif.  A mutant of 
Wrch-1 that cannot be palmitoylated (Wrch-1 SSFV) decreased the ability of Wrch-1 to form 
colonies (Brady et al., 2009). Wrch-1-mediated anchorage-independent growth is also 
regulated by its N-terminus; the removal of the N-terminal auto-inhibitory domain of Wrch-1 
increases anchorage-independent growth (Brady et al., 2009). In addition to FTase and 
GGTase I, another prenyl transferase called geranylgeranyl transferase II (GGTase II) has 
been described, which modifies Rab GTPases (Seabra et al., 1992).  Instead of recognizing 
a CAAX motif, GGTase II recognizes Rab proteins which terminate in CCXX, CC, or CXC 
motif (Khosravi-Far et al., 1992).  Although Wrch-1 ends in an apparent CCXX motif, it is not 
a target for GGTase II (Berzat et al., 2005b). 
 
Most recently, we found that Wrch-1 negatively regulates the kinetics of tight junction 
assembly through binding to the cell polarity protein Par6 in a GTP-dependent manner 
(Brady et al., 2009).  Polarity is important for the proper development and function of  
organisms (Wodarz, 2002), and loss of polarity can contribute to a transformed phenotype 
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(Wodarz and Nathke, 2007).  Proper cell polarity is needed for the formation of apical and 
basolateral membranes during morphogenesis, determination of cell fate during asymmetric 
cell division, and proper development and migration of neuronal axons and dendrites 
(Nelson, 2003).  Although Wrch-1 had no detectable effect on overall cell polarity in a 
confluent monolayer, it had a dramatic impact on the cytoskeleton and multilayering in cells 
grown in three-dimensional culture (Brady et al., 2009).  A precisely regulated level of Wrch-
1 seems to be required, because overexpression of activated Wrch-1 or knockdown of 
Wrch-1 disrupted epithelial cell morphogenesis (Brady et al., 2009).   
  
Wrch-1 localizes to the plasma membrane and to internal membranes including endosomes 
and lysosomes, potentially suggesting a role for Wrch-1 in intracellular trafficking. As stated 
earlier, there is no known "second signal" for Wrch-1 plasma membrane localization; there is 
no identifiable polybasic region, and there is no upstream cysteine available in the C-
terminus for palmitoylation.  However there are many residues in the C-terminal 
hypervariable region that could be substrates for post-translational modification, including 
several lysines (ubiquitination), serines, threonines, and tyrosines (phosphorylation). This 
dissertation will focus on the role of C-terminal tyrosine phosphorylation in regulating the 
localization and function of Wrch-1.  Chapters II and III will focus on the upstream kinases, 
and the mechanism by which C-terminal tyrosine phosphorylation regulates  Wrch-1. 
  
1.5 Cdc42-related GTPases and trafficking.  There are several examples of Cdc42 family 
members that are involved intracellular trafficking.  Cdc42 shares high sequence similarity 
with two other members of the Cdc42 family in addition to Wrch-1 and Chp, TC10 and TCL 
(Figure 1.10).  Similar to Cdc42, TC10 promotes the formation of filopodia, activates JNK, 
and promotes SRF- and NF-κB-mediated transcription (Murphy et al., 1999).  TCL promotes 
the formation of membrane ruffles and lamellipodia (Aspenstrom et al., 2004; Vignal et al., 
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2000).  Interestingly, TC10 and TCL share some overlapping localizations with Wrch-1.  
TC10 localizes mainly to the plasma membrane and intracellular membranes, whereas TCL 
localizes to endosomes.  TC10 localization and biological function are dependent on both 
palmitoyl fatty acid modification of carboxyl terminal cysteine residues upstream of the 
CAAX motif, and on isoprenylation of its CAAX motif (Murphy et al., 2001; Murphy et al., 
1999).  Additionally, TC10 is phosphorylated by CDK5 on Thr197. Palmitoylation and 
phosphorylation also regulate TC10 mediated biological functions. For example, TC10 
regulation of GLUT-4 translocation to the plasma membrane requires palmitoyl-assisted 
localization of TC10 to lipid rafts (Murphy et al., 2001; Murphy et al., 1999).  Additionally, 
phosphorylation at Thr197 by CDK mediates the association of TC10 with lipid rafts, a 
requirement for its ability to modulate insulin-stimulated GLUT4 translocation (Okada et al., 
2008). TCL has been previously shown to associate with early endosomes, and regulate the 
transfer of transferrin from early endosomes to recycling endosomes (de Toledo et al., 
2003).  A proper balance of TCL activity is required for this function, because both loss of 
TCL and constitutive activation of TCL restricts transferrin to early endosomes (de Toledo et 
al., 2003). Furthermore, the C-terminal tail and proper localization were crucial for TCL 
function, because the fusion of C-terminal sequences of TCL to either Cdc42 or TC10 had a 
similar effect on transferrin trafficking (de Toledo et al., 2003).  This further highlights the 
importance of localization in regulating the function of Rho family proteins. Wrch-1 localizes 
to the plasma membrane and internal membranes, and as discussed in this dissertation, its 
localization is regulated by C-terminal terminal phosphorylation.  The mechanisms of Wrch-1 
relocalization and its role in trafficking are addressed in Chapters II and III.   
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1.6 C-terminal Ser/Thr phosphorylation of Ras and Rho proteins. There is increasing 
evidence that phosphorylation of small GTPases is required for both their localization and 
specific functions. In one of the first studies of small GTPase phosphorylation, it was found 
that K-Ras was phosphorylated by PKC (Ballester et al., 1987). In addition to being modified 
by a prenyl group on its C-terminal CAAX motif, K-Ras also possesses an upstream 
polybasic region that is required for proper membrane targeting (Hancock et al., 1990). 
Because of these modifications, K-Ras falls into a broad class of proteins that are also 
anchored into the plasma membrane via a lipid modification and a polybasic region, one of 
which is the myristoylated alanine-rich C kinase substrate (MARCKS).  The lipid 
modifications are thought to insert into the lipid bilayer of the plasma membrane, and the 
basic residues are thought to interact with the positively charged head groups of the 
phospholipids (Leventis and Silvius, 1998).  Previously, it was shown that MARCKS is a 
substrate for PKC phosphorylation, which causes MARCKS to dissociate from the plasma 
membrane by a process known as the "myristoyl-electrostatic switch" (McLaughlin and 
Aderem, 1995).  Subsequently it was found that K-Ras also underwent a similar process, 
where it was phosphorylated and translocated from this plasma membrane, and this 
translocation was then termed a "farnesyl-electrostatic switch" (Bivona et al., 2006). In 
response to PKC-mediated phosphorylation of Ser181 in its C-terminal membrane-targeting 
domain, K-Ras4B translocates from the plasma membrane to the mitochondria, where it 
then promotes apoptosis instead of proliferation (Bivona et al., 2006). Similarly, RalA is a 
target of Aurora-A kinase-mediated phosphorylation at Ser194 and PP2A Aβ-mediated 
dephosphorylation; phosphorylation of this site depletes it from the plasma membrane (Lim 
KH, 2009; Sablina et al., 2007; Wu et al., 2005). Furthermore, AuroraA phosphorylation of 
RalA not only causes translocation from the plasma membrane, but also promotes activation 
of RalA and its effector RalBP1 (Lim KH, 2009 #172).  Other members of the Ras 
superfamily of small GTPases are also phosphorylated: for example, Rap1 is 
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phosphorylated on Ser180 by protein kinase A (Quilliam et al., 1991). Rho family proteins 
whose localization and biological activity are regulated by phosphorylation include RhoA, 
Rnd3/RhoE and TC10. RhoA localization and modulation of cell spreading and migration is 
regulated by PKA-mediated phosphorylation on Ser188, which promotes its binding to 
RhoGDI (Forget et al., 2002; Lang et al., 1996). Rnd3/RhoE is phosphorylated after 
stimulation of PKCα, which results in translocation from the plasma membrane to internal 
membranes, and PKC-mediated phosphorylation is required for Rnd3 to modulate the 
Rho/ROCK pathway (Madigan, 2009 #435). Furthermore, Rnd3 is also phosphorylated by 
ROCK-1 on multiple sites in its N- and C-termini, which then increases the stability of Rnd3 
and alters its subcellular localization (Riento et al., 2005).  The mechanism by which ROCK 
phosphorylation of Rnd3 regulates its activity is thought to be mediated by promoting 
binding of Rnd3 to the αG helix of ROCK-1, which then positions the N-and C-termini of 
Rnd3 in close proximity to the kinase domain of ROCK-1  (Komander et al., 2008).  TC10, 
which is closely related to Wrch-1, is phosphorylated by CDK5 on Thr197, which regulates 
its association with lipid rafts, a requirement for its ability to modulate insulin-stimulated 
GLUT4 translocation (Okada et al., 2008).  Thus, there is significant evidence for the 
functional importance of phosphorylation of small GTPases. 
 
1.7 Src family kinases  V-Src, the first identified oncogene, is the transforming product of 
the Rous Sarcoma virus (Stehelin et al., 1977).  Its cellular counterpart, c-Src, is part of a 
nine-member family of non-receptor tyrosine kinases.  Generally the Src family is divided 
into 2 classes; those with a wide range of expression (Src, Yes, and Fyn) and those that 
have restricted expression (Lyn, Fgr, Hck, Lck, Blk, and Yrc).  In general, Src family kinases 
are involved in cell adhesion assembly and turnover, motility, cell polarity, epithelial cell 
morphogenesis, cell proliferation and survival (Thomas and Brugge, 1997).  Src family 
kinases have 6 functional domains: a myristoylation site (enables interaction with the plasma 
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membrane), a unique domain, SH2 and SH3 domains (for interactions with other proteins), a 
kinase domain (containing an autophosphorylation site), and a C-terminal regulatory 
domain.  Src is activated by undergoing a conformational change from a "closed" state to an 
"open" state.  Normally the SH2 domain of Src binds to a phospho group at Y527; when this 
happens, Src adopts a "closed" and inactive conformation.  De-phosphorylation at Y527 
relieves this auto-inhibition, and Src is then in an "open" conformation (Cooper et al., 1986; 
Cooper and King, 1986).  After Src is in an "open" conformation, it can auto-phosphorylate 
on Y416 within the kinase domain, rendering the kinase fully active (Kmiecik et al., 1988; 
Kmiecik and Shalloway, 1987).  
  
There are several well characterized effectors that Src utilizes to promote biological 
functions, the most well studied effector being FAK (focal adhesion kinase) (Lipfert et al., 
1992). As the name suggests, FAK is a non-receptor tyrosine kinase that is localized to and 
involved in focal adhesion formation and turnover.  In primary chicken embryo fibroblasts 
(CEFs), v-Src completely disrupts all focal adhesions over a 16-24 hour period, which 
results in marked cell detachment (Fincham et al., 1995). Subsequently, it was shown that v-
Src induced tyrosine phosphorylation of FAK which mediated focal adhesion loss that 
accompanies transformation (Fincham and Frame, 1998; Fincham et al., 1995).  Cas (Crk-
and Src-associated substrate) is another Src effector that is involved in focal adhesion 
formation and turnover, most notably downstream of integrin signaling (Sakai et al., 1994).  
In addition to modulating focal adhesions, Src has also been implicated in regulating cell 
proliferation through the transcription factor STAT3; the levels of STAT3 are elevated in v-
Src transformed cells, and dominant-negative STAT3 inhibits v-Src mediated transformation 
(Bromberg et al., 1998).  
 
Src localizes to several compartments within the cell including the plasma membrane, peri-
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nuclear region, endosomes, and focal adhesions (Kaplan et al., 1992).  Most active Src is 
found either at the plasma membrane or at focal adhesions (Yamamoto et al., 2002).  Src 
can traffick to and from endosomes within the cell after extracellular stimuli (Donepudi and 
Resh, 2008; Sandilands and Frame, 2008).  Studies have shown that upon growth factor 
stimulation, inactive c-Src at the peri-nuclear region can translocate via recycling 
endosomes to the plasma membrane where it is active (Sandilands and Frame, 2008). 
Additionally, Src can traffick with RTKs such as EGFR, VEGFR, and FGFR.   
 
1.8 EGFR family members  Epidermal growth factor receptors (EGFRs) are members of 
the family of receptor tyrosine kinases (RTKs).  The members of this family include 
EGFR/ErbB1/HER1, ErbB2/Neu/HER2, ErbB3/HER3, and ErbB4/HER4 (Hynes and Lane, 
2005).  All the members of this family have an extracellular ligand-binding domain, a 
transmembrane domain, and a cytoplasmic protein-kinase domain. EGFR family members 
are well known for their roles in cell proliferation, angiogenesis, adhesion, migration, and 
invasion (Hynes and Lane, 2005).  EGFR utilizes several effector pathways to promote 
biological effects, the most well characterized being the Ras/Raf/MEK/ERK pathway (Gupta 
and Davis, 1994; Hill et al., 1993; Sasaoka et al., 1994). Activation of the Ras/Raf/MEK/ERK 
pathway by EGFR results in activation of c-myc and c-jun transcription factors, which leads 
to increased transcription of genes involved in cell proliferation and survival (Hill et al., 
1993).  EGFR also activates PI3K (phosphoinositide 3-kinase), a lipid kinase that 
phosphorylates the 3' position hydroxyl group of the inositol ring of phosphatidylinositol 
(PtdIns) (Laffargue et al., 1999). PI3K drives several biological outputs including cell growth, 
proliferation, survival, differentiation, and motility (Kurosu et al., 1997; Roche et al., 1998).  
 
Ligand binding to the EGFR family of receptors induces the formation of different homo- and 
heterodimers, which in turn activates the kinase domain (Ullrich and Schlessinger, 1990).  
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The kinase domain then autophosphorylates the receptor, creating binding sites for SH2 
domains in other proteins, subsequently leading to the activation of various intracellular 
signaling pathways (Ullrich and Schlessinger, 1990).  The duration and intensity of 
intracellular signaling initiated by EGFR activation is tightly regulated in cells.  For example, 
protein phosphatases can interfere with the amplitude and duration of EGFR signaling 
responses (Samuels et al., 1993).  Additionally, signaling initiated by there receptors is 
attenuated by internalization and subsequent degradation of these receptors.  Following 
ligand binding, EGFRs are rapidly internalized via multiple different pathways (Dikic and 
Giordano, 2003).  After internalization, these receptors are initially delivered to early 
endosomes, which then mature into late endosomes and multi-vesicular bodies.  In the 
multi-vesicular bodies, the receptors are either recycled back to the plasma membrane, or 
directed to the lysosomes for destruction (Lai et al., 1989a; Lai et al., 1989b; Vieira et al., 
1996).   
  
There are two main pathways that EGFR utilizes for receptor internalization following ligand 
stimulation; ubiquitin-dependent and ubiquitin-independent pathways (Dikic, 2003; Dikic and 
Giordano, 2003).  It widely accepted that the Cbl family of E3 ligases is a major contributor 
to ubiquitin-dependent EGFR endocytosis. E3 ligases are a class of proteins that, in 
conjunction with E1 and E2 ubiquitin conjugating ligases, allow attachment of a ubiquitin 
molecule onto a lysine in a target protein.   These ubiquitin groups can be added as a single 
monomer, or in poly-ubiquitin chains.  Typically mono-ubiquitination acts as a signal for 
intracellular trafficking, and poly-ubiquitin signals for destruction by the proteosome (Pickart 
and Eddins, 2004).   As previously stated, after EGF stimulation, EGFR family members 
form dimers, and subsequently become autophosphorylated. These autophosphorylation 
sites serve as docking sites for the Cbl family of E3 ligases (Y1045 in EGFR) (Schmidt and 
Dikic, 2005).  Upon binding to EGFR, Cbl ubiquitinates the receptor.  After ubiquitination of 
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EGFR, the receptor trafficks to endosomes, where it can then either be sorted to lysosomes 
for destruction, or to recycling endosomes for recycling back to the plasma membrane 
(Dikic, 2003).   
  
Cbl can also mediate EGFR internalization through a ubiquitin-independent pathway, 
through its association with CIN85 (Petrelli et al., 2002).  The SH3 domain of Cbl binds to a 
PxxP-motif in CIN85 (where x can be any amino acid).  Proline-rich motifs in CIN85 mediate 
its association with SH3 domains of endophilins, a family of proteins that are able to regulate 
curvature of the plasma membrane during the early steps of endocytosis (Schmidt et al., 
1999).  EGFR can utilize interaction with the Cbl-CIN85-endophilin complex, to traffick to 
endosomal compartments.  Inhibition of the Cbl-CIN85-endophilin complex was sufficient to 
block EGFR endocytosis, independent of the E3 ligase activity of Cbl (Petrelli et al., 2002).  
 
1.9 Rho GTPases in cancer   The process of carcinogenesis involves self-sufficiency in 
growth signal, insensitivity to anti-growth signals, the evasion of apoptosis, sustained 
angiogenesis, limitless replicative potential and eventually the initiation of migration and 
invasion into nearby and distant sites (Hanahan and Weinberg, 2000).  Rho GTPases are 
known to regulate several of these processes, which suggests that, like Ras GTPases, Rho 
GTPases may be aberrantly regulated in human cancers.  Ras proteins are mutated in 30% 
of all human cancer; however, there have been no identified naturally occurring mutations in 
Rho GTPases, with the notable exception of RhoH/TTF (Pasqualucci, 2001 #39; 
Preudhomme, 2000 #237).  Although Rho GTPases are not mutationally activated in human 
cancers, there are documented examples of overexpression of the GTPase itself or of their 
positive regulators, or loss of negative regulators.  Indeed, misregulation of Rho GTPases 
leads to increased proliferation, dedifferentiation, invasion and metastasis (Ellerbroek et al., 
2003; Sahai and Marshall, 2002).   
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As previously mentioned, RhoH is the only Rho GTPase that is reported to be genetically 
altered in human cancers (Pasqualucci et al., 2001; Preudhomme et al., 2000). RhoH, also 
known as TTF (translocated three four), is expressed specifically in hematopoietic cells 
(Dallery et al., 1995), and plays a role in both non-Hodgkins lymphoma and multiple 
myeloma (Preudhomme et al., 2000).   The rearrangement is caused by a t(3;4)(q27;p11-
13) chromosomal gene translocation, which results in the expression of a BCL3/LAZ3 fusion 
protein (Dallery et al., 1995). Additionally, RhoH, similar to the Rnd proteins, lacks the 
conserved residue analogous to G12 and Q61 residues in other Rho proteins, and is likely 
to be GTPase-deficient (Li et al., 2002).  Although there are no other known examples of 
genetic modifications of Rho proteins, several Rho GTPases have been reported to have 
altered expression in human cancers, including RhoA, RhoB, RhoC, Rac1, Rac1b, Rac2, 
Rac3, RhoG, Cdc42, RhoH/TTF, Rnd3/RhoE (Ellenbroek and Collard, 2007), and in some 
cases Wrch-1 (Kirikoshi and Katoh, 2002).  Specifically RhoA is overexpressed in tumors of 
the colon, breast, and lung (Fritz et al., 1999), as well as testicular germ cells (Kamai et al., 
2001) and head and neck squamous cell carcinoma (Abraham et al., 2001).    RhoC 
overexpression is found in breast cancer, is involved in driving the phenotype of 
inflammatory breast cancer (van Golen et al., 2000) and has been shown to play a role in 
promoting metastasis of these tumors (Wu et al., 2004).  
 
In addition to Rho GTPase overexpression, aberrant RhoGEF regulation, such as 
overexpression or constitutive activation, has been implicated in human cancers.  For 
example, chromosomal rearrangements in leukemia can result in a MLL-LARG chimera that 
contributes to Rho family activation and tumorigenesis (Kourlas et al., 2000).   Additionally, 
downregulation of negative regulators of Rho GTPase activity has also been documented.  
For example, genomic deletion or promoter methylation results in downregulation of 
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RhoGAPs such as DLC-1 and DLC-2 in hepatocellular and breast carcinoma (Ching et al., 
2003; Goodison et al., 2005; Wong et al., 2003; Yuan et al., 2003a; Yuan et al., 2003b).  
Furthermore, down-regulation and overexpression of RhoGDIs has been reported in several 
types of human cancer, however the exact mechanism of how these contribute to tumor 
progression is still under investigation (Dovas and Couchman, 2005; Zhang and Zhang, 
2006).   
 
As previously stated, Wrch-1 was initially discovered as a Wnt responsive gene, whose 
expression (measured by mRNA) was increased in response to Wnt-1 signaling in Wnt-1 
transformed cells, Wnt-1 transgene induced mouse mammary tumors, and Wnt-1 retrovirus 
infected cells (Tao et al., 2001).  When Wrch-1 is mutationally activated (Q107L, analogous 
to a Ras Q61L mutation) it phenocopies Wnt-1 morphological transformation of mammary 
cells (Tao et al., 2001).  Interestingly, Wrch-1 message levels are regulated by Wnt-1 in a β-
catenin-independent manner (Tao et al., 2001). Wrch-1 has been shown to be involved in 
several mechanisms involved in tumorigenesis. Wrch-1 overexpression increases migration 
in both osteoclasts and HeLa cells (Brazier et al., 2009; Chuang et al., 2007; Ory et al., 
2007).  Conversely, Wrch-1 depletion led to an increase in focal adhesions, by regulating 
myosin light chain, and a decrease in migration (Chuang et al., 2007). Wrch-1-mediated 
migration is thought to be accomplished through activation of Akt and JNK because Wrch-1 
is necessary for wound-healing mediated by Akt and JNK activation (Chuang et al., 2007).  
Wrch-1 expression reduced osteoclast adhesion onto vitronectin but not fibronectin and also 
increased osteoclast precursor aggregation (Brazier et al., 2009). Wrch-1 has also been 
shown to promote anchorage-independent growth in several cell types (Berzat et al., 2005b; 
Brady et al., 2009). Most recently, it was found that Wrch-1 negatively regulates the kinetics 
of tight junction assembly through binding to the cell polarity protein Par6 in a GTP 
dependent manner (Brady et al., 2009).  Although Wrch-1 had no detectable effect on 
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overall cell polarity in a confluent monolayer, it had a dramatic impact on the cytoskeleton 
and multilayering in cells grown in three-dimensional culture (Brady et al., 2009).  A proper 
level of Wrch-1 seems to be required, because overexpression of activated Wrch-1 or 
knockdown of Wrch-1 disrupted epithelial cell morphogenesis (Brady et al., 2009).  Taken 
together, these data suggest that Wrch-1 is involved in carcinogenesis, however Wrch-1 
levels have been shown to be both up- and down-regulated, depending on the type of 
cancer (Kirikoshi and Katoh, 2002).  Further studies need to be done to address the 
mechanism of Wrch-1 regulation, and how this regulation contributes to Wrch-1 mediated 
biological functions. In this dissertation I have examined the role of C-terminal tyrosine 
phosphorylation of Wrch-1 in regulating both the localization and biological activity of Wrch-
1. 
 
1.10 Evaluating the role of C-terminal tyrosine phosphorylation in regulating the 
localization and function of Wrch-1.  As stated previously, Wrch-1 expression is regulated 
by Wnt-1 signaling (Taneyhill and Pennica, 2004; Tao et al., 2001), and by RANKL 
stimulation in osteoclasts (Brazier et al., 2009; Brazier et al., 2006; Ory et al., 2007). 
Although Rho GTPases are regulated by GEFs and GAPs, currently there are no identified 
GEFs, GAPs, or GDIs known to interact with and regulate Wrch-1.   In vitro, Wrch-1 has a 
very high rate of GDP/GTP exchange, suggesting that Wrch-1 may be constitutively GTP-
bound in cells (Shutes et al., 2006). However, in biological assays, the GTPase-insensitive 
mutant of Wrch-1 (Q107L) shows higher activity than wild-type Wrch-1 (Berzat et al., 2005b; 
Brady et al., 2009; Brazier et al., 2009; Chuang et al., 2007; Ory et al., 2007; Ruusala and 
Aspenstrom, 2008; Saras et al., 2004), suggesting that there is a GAP that inactivates Wrch-
1 which has yet to be identified. Additionally, Wrch-1 is palmitoylated instead of prenylated 
(Berzat et al., 2005b), and does not interact with RhoGDI-1 (Berzat et al., 2006).  While 
most Rho proteins utilize a "second signal" for proper membrane localization, currently, 
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there is no known "second signal" for Wrch-1. However, while in search for a "second 
signal" for Wrch-1 membrane targeting, Anastacia Berzat, a former lab member, found that 
Wrch-1 was tyrosine phosphorylated in response to serum stimulation. In this dissertation, I 
have investigated the mechanisms controlling both tyrosine phosphorylation of Wrch-1, and 
how this phosphorylation event regulates the localization, trafficking and biological functions 
of Wrch-1.  Chapter II is dedicated to defining the residue of Wrch-1 that is tyrosine 
phosphorylated in response to serum and the role of Src in mediating C-terminal 
phosphorylation of Wrch-1. Additionally Chapter II focuses on the mechanism by which this 
C-terminal tyrosine phosphorylation at Y254 regulates the localization and biological 
functions of Wrch-1 and uncovers a putative endosomally restricted GAP that 
downregulates Wrch-1 activity.   Chapter III focuses on defining the role of EGFR in 
regulating C-terminal phosphorylation at Y254. Chapter III also focuses on how 
phosphorylation at Y254 regulates the trafficking of Wrch-1, and how it alters protein 
complex formation with EGFR, Src, Cbl, etc.  Chapter IV summarizes the findings of this 
dissertation and suggests further studies on how both tyrosine phosphorylation and other 
posttranslational modifications play a role in regulating the localization and function of Wrch-
1.  These findings and potential future directions will contribute to a better understanding of 
how posttranslational modifications, especially tyrosine phosphorylation, can play a critical 
role in regulating small GTPases.  
 
 
 
 
 
 
 
 2 
 
  
CHAPTER II 
 
REGULATION OF THE RHO FAMILY SMALL GTPASE WRCH-1 BY SRC-MEDIATED 
TYROSINE PHOSPHORYLATION OF ITS C-TERMINAL MEMBRANE TARGETING 
REGION  
 
2.1 Abstract 
Wrch-1 is an atypical Rho family small GTPase with roles in migration, epithelial cell 
morphogenesis, osteoclastogenesis and oncogenic transformation.  Here, we observed 
rapid relocalization of Wrch-1 from plasma membrane to endosomes upon serum 
stimulation.  Exploration of the basis for this shift revealed a requirement for serum-
stimulated tyrosine phosphorylation of Wrch-1 at residue Y254 within its C-terminal 
membrane targeting domain, mediated by the non-receptor tyrosine kinase Src.  Genetic or 
pharmacological loss of Src kinase activity blocked both phosphorylation and relocalization 
of Wrch-1. Functionally, Y254 was required for proper Wrch-1 modulation of cystogenesis in 
three-dimensional culture, and the phosphodeficient mutant, Y254F, was enhanced in Wrch-
1-mediated anchorage-independent growth.  Mechanistically, C-terminal tyrosine 
phosphorylation and subsequent relocalization of Wrch-1 downregulated its ability to interact 
with and activate its effectors by decreasing active, Wrch-1-GTP, presumably by enhancing 
proximity to a GAP.  Phosphodeficient Wrch-1(Y254F) remained trapped at the plasma 
membrane and GTP-bound, and continued to recruit and activate its effector PAK even 
upon serum stimulation.  In contrast, a phosphomimetic mutant, Y254E, was constitutively 
endosomally localized and GDP-bound, and failed to recruit PAK unless mutated to become 
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GAP-insensitive. C-terminal tyrosine phosphorylation thus represents a new paradigm in 
posttranslational control of small GTPase localization, activation and biological function.    
 
2.2 Introduction 
Rho family proteins are Ras-related small GTPases that regulate cytoskeletal organization 
and dynamics, cell adhesion, motility, trafficking, proliferation and survival (Jaffe and Hall, 
2005). Rho GTPases function as tightly regulated molecular switches, cycling between the 
active GTP-bound state and the inactive GDP-bound state with assistance from positive 
regulatory GEF proteins and negative regulatory GAPs. Rho GTPases are also regulated by 
their subcellular localization, which is directed by sequences and post-translational 
modifications in their C-terminal hypervariable membrane targeting regions.  Most Rho 
GTPases are post-translationally modified by an isoprenoid lipid attached permanently to 
their C-terminal CAAX motifs (Adamson et al., 1992), and their correct localization requires a 
second signal which usually consists of a polybasic region or a palmitate fatty acid upstream 
of the CAAX motif (Lebowitz et al., 1997; Michaelson et al., 2001; Williams, 2003; Ziman et 
al., 1993).  In addition, Rho GTPases typically interact with Rho-guanine nucleotide 
dissociation inhibitors (RhoGDIs), that bind their prenyl groups and sequester them from 
membranes (Isomura et al., 1991; Takai et al., 1995). Interaction of the GTP-bound proteins 
with their downstream effectors at specific locations then elicits their biological functions. 
 
Wrch-1, also designated RhoU and Wrch1, is an atypical member of the Cdc42 subgroup of 
Rho GTPases that induce the formation of actin microspikes and filopodia.  Although it 
shares 57% sequence identity with Cdc42 and 61% sequence identity with its closest 
relative, Chp/Wrch-2, Wrch-1 shares only partially overlapping localization and effector 
interactions with these proteins, and its activity is regulated in a distinct manner.  Like 
Cdc42, Wrch-1 activity leads to activation of PAK1 and JNK (Chuang et al., 2007; Tao et al., 
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2001), formation of filopodia (Ruusala and Aspenstrom, 2008; Saras et al., 2004) and both 
morphological (Brady et al., 2009) and growth transformation in multiple cell types (Berzat et 
al., 2005b; Brady et al., 2009).  In addition, Wrch-1 also regulates focal adhesion turnover 
(Chuang et al., 2007; Ory et al., 2007), negatively regulates the kinetics of tight junction 
formation (Brady et al., 2009), plays a required role in epithelial morphogenesis (Brady et 
al., 2009), and modulates osteoclastogenesis (Brazier et al., 2009; Brazier et al., 2006; Ory 
et al., 2007). Initially discovered as a Wnt-responsive gene capable of phenocopying Wnt 
morphological transformation in mouse mammary epithelial cells when mutationally 
activated (Taneyhill and Pennica, 2004; Tao et al., 2001), Wrch-1 is transcriptionally 
upregulated in MEFs by Wnt in a JNK-dependent manner (Schiavone et al., 2009) and in 
bone marrow macrophages during osteoclastogenesis by RANKL stimulation (Brazier et al., 
2006).  Recently its expression has also been shown to be responsive to gp130-class 
cytokines, which transcriptionally regulate Wrch-1 expression via STAT3 (Schiavone et al., 
2009).  Finally, Wrch-1 expression has been shown to be upregulated in some cancers but 
downregulated in others (Kirikoshi and Katoh, 2002). Thus, modulation of Wrch-1 activity at 
the level of expression is a common event.  However, because it is a GTP-binding protein, a 
more dynamic regulation of Wrch-1 activity is also required.    
 
Wrch-1 is thought to be largely GTP-bound due to a high intrinsic exchange rate 
(Aspenstrom et al., 2007; Shutes et al., 2004), and no GEFs or GAPs have yet been 
identified.  However, mutationally activated (Q107L, analogous to Q61L in Ras or Cdc42) 
Wrch-1 is more active than wild type Wrch-1 (Berzat et al., 2005b; Brady et al., 2009; 
Brazier et al., 2009; Ory et al., 2007; Tao et al., 2001), indicating that at least one or more 
GAPs remain to be identified.  In addition, Wrch-1 contains a 46-amino acid N-terminal 
extension that we and others have shown confers negative regulation to Wrch-1 activity 
(Shutes et al., 2004). This extension contains proline-rich SH3-binding PxxP motifs that 
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promote interaction of Wrch-1 with Grb2, Nckβ and PLCγ1 (Saras et al., 2004; Shutes et al., 
2004), and it is thought that Grb2 binding helps to relieve the inhibition of the N-terminus 
towards Wrch-1 activity (Shutes et al., 2004).  
 
In addition to regulation of its activity at the level of expression as well as by at least one 
putative GAP and relief of its autoinhibitory domain, Wrch-1 function requires post-
translational lipid modification of its C-terminal membrane targeting domain.  Unlike Cdc42, 
Wrch-1 does not terminate in a CAAX motif that is prenylated, but instead terminates in a 
CFV motif that is palmitoylated (Berzat et al., 2005b).  Further, lacking a prenyl group, Wrch-
1 does not bind RhoGDI (Berzat et al., 2005a). We have shown previously (Berzat et al., 
2005b; Brady et al., 2009) that palmitoylation, a dynamically regulated lipid modification 
(Mumby et al., 1994), is required for both the subcellular localization and biological activities 
of Wrch-1.  However, whereas both prenylation and the polybasic region of Cdc42 are 
required for its proper localization and function (Williams, 2003), the identity of additional 
signals governing Wrch-1 is unknown.  
 
There is increasing evidence that C-terminal serine/threonine phosphorylation of small 
GTPases near the isoprenoid moiety is required for both their localization and specific 
functions. In response to PKC-mediated phosphorylation of Ser181 in its C-terminal 
membrane targeting domain, K-Ras4B translocates from the plasma membrane to the 
mitochondria, where it then promotes apoptosis instead of proliferation (Bivona et al., 2006). 
RalA is a target of Aurora-A kinase-mediated phosphorylation at Ser194 (Wu et al., 2005) 
and PP2A Aβ-mediated dephosphorylation (Blake et al., 2000); phosphorylation of this site 
depletes it from the plasma membrane (Lim KH, 2009). Rap1 is phosphorylated on Ser180 
by protein kinase A  (Lerosey et al., 1991; Quilliam et al., 1991) and RhoA localization and 
modulation of cell spreading and migration is regulated by PKA-mediated phosphorylation 
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on Ser188 (Ellerbroek et al., 2003; Lang et al., 1996), which promotes its binding to RhoGDI 
(Ellerbroek et al., 2003).  PKCα (Riento, 2005 #149; Madigan, 2009 #435) and ROCK 
(Riento et al., 2005) stimulate phosphorylation of Rnd3/RhoE that results in translocation 
from the plasma membrane to internal membranes, and PKC-mediated phosphorylation is 
required for Rnd3 to modulate the Rho/ROCK pathway (Madigan, 2009 #435). TC10 is 
phosphorylated by CDK5 on Thr197, which regulates its association with lipid rafts, a 
requirement for its ability to modulate insulin-stimulated GLUT4 translocation (Okada et al., 
2008).  Thus, there is significant evidence for the functional importance of C-terminal 
serine/threonine modification of small GTPases. 
 
In the present study, we sought to determine which C-terminal elements in addition to 
palmitoylation contribute to the regulation of Wrch-1 subcellular localization and biological 
activity.  Unlike the several small GTPases shown to be substrates for C-terminal Ser/Thr 
phosphorylation, the minimal C-terminal membrane targeting sequence of Wrch-1 does not 
contain a suitable serine or threonine residue.  However, it does contain a potentially 
phosphorylatable tyrosine residue.  Further, endosomal localization is often dynamically 
regulated by external signals such as those supplied by serum factors that stimulate 
engagement of growth factor receptor tyrosine kinases and their associated nonreceptor 
tyrosine kinase partners (Sorkin and Von Zastrow, 2002). In this report, we describe our 
discovery that serum stimulates Src-mediated tyrosine phosphorylation of Wrch-1 and its 
translocation from plasma membrane to endosomes, and that a specific tyrosine residue in 
the C-terminal membrane targeting domain of Wrch-1 regulates its subcellular localization, 
GTP/GDP-binding status, effector activation and biological activities.  Thus, we have 
identified C-terminal tyrosine phosphorylation as a novel mechanism for regulation of small 
GTPase activity.  
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2.3 Results 
2.3.1 Wrch-1 rapidly relocalizes from the plasma membrane to endosomal membranes 
in response to serum stimulation.  We have shown previously that the atypical Rho family 
small GTPase, Wrch-1, localizes to both plasma membrane and internal compartments, 
including endosomal membranes (Berzat et al., 2005b).  Because endosomal localization of 
other proteins, including some Rho GTPases, can be directed by external stimuli such as 
serum-stimulated engagement of growth factor receptors, and is therefore dynamically 
regulated, we sought to determine whether Wrch-1 targeting to endosomes was similarly 
regulated.  To that end, we serum-starved overnight H1299 nonsmall cell lung cancer 
(NSCLC) cells transiently expressing EGFP-tagged Wrch-1 (designated GFP-Wrch-1) and 
then stimulated them with serum for 15 min.  Whereas Wrch-1 was localized to both the 
plasma membrane and endosomal membranes in serum-starved cells, it underwent rapid 
relocalization from the plasma membrane to internal membranes upon serum stimulation 
(Figure 2.1).  Increased endosomal localization of Wrch-1 was confirmed using transferrin, a 
marker for endocytic membranes (Figure 2.1).  These data indicate that Wrch-1 subcellular 
localization to plasma membrane and endosomes is both dynamic and regulated by 
upstream signals.   
 
2.3.2 Relocalization is dependent on the presence of a tyrosine at position 254 in the 
Wrch-1 C-terminal membrane targeting domain.  We had previously determined that the 
carboxy-terminal nine amino acids of Wrch-1 are sufficient for its proper subcellular 
localization (Berzat et al., 2005b), and that mutation of the palmitoylated cysteine residues 
therein results in cytosolic accumulation (Berzat et al., 2005b).  Within this sequence of 
WWKKYCCFV, the single tyrosine at residue 254 (Y254) stood out as a potential site of 
regulation in response to serum.  Further, because subcellular localization dictates the 
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function of small GTPases, we hypothesized that Y254 becomes tyrosine phosphorylated in 
response to serum stimulation and that this phosphoryation event modulates Wrch-1 
subcellular localization and activity.  
 
To examine whether Y254 is required for the serum-stimulated re-localization of Wrch-1, we 
generated a Y>F mutation at position 254 [designated Wrch-1(Y254F)].  We then 
transfected H1299 cells with GFP-Wrch-1 or GFP-Wrch-1(Y254F) and compared the 
localization of the two proteins under basal conditions to its localization both in the absence 
of serum and after serum stimulation.  We observed that the putatively phosphodeficient 
Wrch-1(Y254F) was preferentially localized to the plasma membrane compared to wild type 
Wrch-1 and was resistant to serum-stimulated relocalization:  rather than being relocalized 
to endosomal compartments, Wrch-1(Y254F) remained trapped on the plasma membrane 
upon serum stimulation (Figure 2.2A).  Further, cells expressing this nonphosphorylatable 
mutant displayed an exaggeratedly rounded phenotype under basal serum-containing 
conditions, which was similar to that seen in serum-starved cells expressing only WT Wrch-1 
(Figure 2.2A). 
 
These results were consistent with our hypothesis that Wrch-1 becomes tyrosine 
phosphorylated on Y254 in response to serum stimulation, and that this phosphorylation 
event is responsible for serum-stimulated relocalization of Wrch-1.  In order to confirm that 
Wrch-1 was tyrosine phosphorylated at Y254, we first transfected HA-tagged Wrch-1 and 
Wrch-1(Y254F) into H1299 cells, and then immunoprecipitated Wrch-1 with an anti-HA 
antibody, followed by western blotting using an anti-phosphotyrosine antibody to probe for 
phosphotyrosine on the immunoprecipitated Wrch-1. We observed that Wrch-1 but not 
Wrch-1(Y254F) was detected by anti-phosphotyrosine following serum stimulation (Figure 
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2.2B), confirming that Wrch-1 is tyrosine phosphorylated and suggesting that Y254 is the 
major site of serum-stimulated phosphorylation.   
 
Interestingly, we also determined that basal subcellular localization of Wrch-1 requires less 
targeting information than does either tyrosine phosphorylation or serum-stimulated 
relocalization.  We had determined previously that the last 9 amino acids in the C-terminus 
of Wrch-1 are sufficient for proper basal localization of Wrch-1 (Berzat et al., 2005b).  
Surprisingly, we found that this short sequence [designated “9 aa tail”] (Figure 2.3A) was not 
sufficient to support either tyrosine phosphorylation (Figure 2.3B) or serum-stimulated 
relocalization (Figure 2.3C).  We speculated that 9 amino acids was an insufficient length to 
allow binding of the kinase.  Therefore we extended it, generating an additional GFP-fusion 
protein comprising 19 amino acids of the Wrch-1 C-terminus [designated “19 aa tail”, which 
still contains only a single tyrosine residue, see Figure 2.3A], and performed the same 
experiments as before.  We found that 19 residues of the Wrch-1 C-terminus was a length 
sufficient both for tyrosine phosphorylation (Figure 2.3B) and for relocalization in response 
to serum stimulation (Figure 2.3C).  A longer tail (39 aa) was indistinguishable from the 19 
amino acid tail and from full length Wrch-1 (data not shown).  Together, these data indicate 
that relocalization of Wrch-1 requires additional sequences compared to basal localization, 
perhaps to allow efficient kinase binding to the region encompassing Y254. 
 
2.3.3 Src can phosphorylate Wrch-1, and Src tyrosine kinase activity is required for 
both tyrosine phosphorylation and serum-stimulated relocalization of Wrch-1.  The 
nonreceptor tyrosine kinase Src transmits signaling from several serum-responsive growth 
factor receptor tyrosine kinases.  Further, Src has many substrates, not all of which have 
been defined clearly.  We speculated that Src could phosphorylate Wrch-1 on Y254, and 
indeed we found that the Src family kinase inhibitor SU6656 effectively blocked tyrosine 
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phosphorylation of Wrch-1 (Figure 2.4A). At the concentration that we used (5 µM), SU6656 
is reported to inhibit tyrosine kinases Src, Fyn, Yes, and Lyn (Bain et al., 2007).  To test 
whether Src alone was sufficient to phosphorylate Wrch-1, we expressed HA-Wrch-1 either 
in MEFs that are genetically deficient in Src, Yes, and Fyn  (SYF-/-) or in MEFs that retain 
Src but are deficient in Yes and Fyn (YF-/-).  We found that Wrch-1 was tyrosine 
phosphorylated in YF-/- MEFs but not in SYF-/- MEFs, indicating that Src is required for 
tyrosine phosphorylation of Wrch-1 (Figure 2.4B). These data indicate that Src functions 
upstream of Wrch-1 to mediate its tyrosine phosphorylation, but do not indicate whether Src 
kinase enzymatic activity is required.  To address this question, we co-transfected HA-Wrch-
1 or HA-Wrch-1(Y254F) along with either constitutively active or kinase-deficient Src and 
then measured the levels of phosphotyrosine Wrch-1 by IP/western blot.  We found that 
Wrch-1 was tyrosine phosphorylated in the presence of kinase-active Src(Y528F) but not 
kinase-deficient Src(K297R), and that the Y254 residue of Wrch-1 was required for this 
phosphorylation, as Wrch-1(Y254F) was not phosphorylated regardless of Src kinase 
activity (Figure 2.4C).  These data support a requirement for Src kinase activity in order for 
Wrch-1 to become tyrosine phosphorylated on Y254, but do not address whether the 
phosphorylation is direct or indirect. To answer this question, we performed an in vitro 
kinase assay with recombinant purified Src and GST-Wrch-1.  We found that Wrch-1 was 
directly phosphorylated by Src in vitro (Figure 2.4D), consistent with the possibility that it 
may be phosphorylated directly in vivo.  
 
Having established that Wrch-1 could be a substrate of Src kinase activity, and that the 
Y254 residue of Wrch-1 that is required for serum-stimulated relocalization is also the major 
site of Src-stimulated phosphorylation, we wished to test whether Src kinase activity is 
required for serum-stimulated relocalization of Wrch-1.  To do this, we serum-starved cells 
expressing GFP-Wrch-1, treated them with SU6656 (5 µM) for 1 h, then serum-stimulated 
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them as above.  We found that SU6656 prevented Wrch-1 relocalization in response to 
serum stimulation (Figure 2.4E).  Collectively, these results indicate that Src tyrosine kinase 
activity is required for both the tyrosine phosphorylation and relocalization of Wrch-1. 
 
2.3.4 Phosphorylatable residue Y254 regulates Wrch-1-mediated transformation.  
Correct subcellular localization is critical to regulate the biological functions of Rho GTPases 
(Etienne-Manneville and Hall, 2002).  Therefore, we hypothesized that tyrosine 
phosphorylation, which alters the subcellular localization of Wrch-1, also likely alters at least 
some of its biological functions.  We have shown previously that both wild type and 
constitutively active Wrch-1(107L) are capable of inducing anchorage-independent growth 
transformation such as colony formation in soft agar (Berzat et al., 2005b; Brady et al., 
2009).  In addition, we have shown that endogenous Wrch-1 is required for correct epithelial 
cell morphogenesis (Brady et al., 2009) and that a nonpalmitoylated mutant of Wrch-1 that 
fails to localize correctly to the plasma membrane is unable to modulate either of these 
biological functions (Berzat et al., 2005b; Brady et al., 2009).  Therefore, we sought to 
assess the role of the tyrosine phosphorylatable residue Y254 in regulating Wrch-1-
mediated anchorage-independent growth and epithelial morphogenesis. To do so, we first 
generated polarizable MDCKII epithelial cell lines stably expressing either HA-Wrch-1 or 
phosphodeficient HA-Wrch-1(Y254F) in both the WT and 107L backgrounds, and confirmed 
that they expressed equivalent amounts of each protein (Figure 2.5A, bottom panel). We 
then seeded these cells into soft agar and allowed them to grow in an anchorage-
independent manner for 14 days, after which colony formation was quantitated.  We 
predicted that the phosphodeficient Y254F mutant, which we have shown here traps Wrch-1 
at the plasma membrane and prevents relocalization to endosomal compartments, would 
display enhanced transforming ability.  In agreement with this prediction, we found that cells 
expressing either of the Y254F mutants formed a significantly increased number of large 
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colonies (>15 cells in diameter) in soft agar when compared to cells expressing parental 
phosphorylatable Wrch-1 proteins (Figure 2.5A).  These results indicate that tyrosine 
phosphorylation of Y254 would represent a negative regulatory control of Wrch-1 biological 
activity. 
 
2.3.5 Phosphorylatable residue Y254 regulates Wrch-1-mediated epithelial 
morphogenesis.   Several Rho family small GTPases are required for cystogenesis in a 3-
dimensional environment (Bryant and Mostov, 2008). In particular, Cdc42 is thought to be a 
master regulator of lumen development in tube and cyst structures, by virtue of its ability to 
regulate the Par6/atypical PKC polarity complex (Bryant and Mostov, 2008). Wrch-1 also 
binds Par6/aPKC, and we have demonstrated previously that a precise balance of 
endogenous Wrch-1 is also required for proper cystogenesis in a 3-dimensional 
environment: either too little or too much Wrch-1 causes disruption of the formation of 
normal, single lumen-containing, hollow cyst structures (Brady et al., 2009), and Cdc42 is 
unable to compensate for the loss of Wrch-1.  Therefore we wished to examine the effect of 
Wrch-1 tyrosine phosphorylation on this crucial Wrch-1-mediated function.  To this end, we 
performed cystogenesis assays and evaluated the formation of hollow cysts of MDCKII cells 
in 3-dimensional culture. MDCKII cells expressing phosphorylatable or phosphodeficient 
[Y254F] Wrch-1 were seeded in a matrix of collagen I.  Cysts were allowed to form over a 
period of 10 days, after which they were stained for Texas Red-phalloidin to image the cyst 
structures. If phosphorylation at Y254 is a negative regulator of Wrch-1 activity, as 
suggested by the increased numbers of colonies formed in soft agar by cells expressing the 
phosphodeficient mutant Y254F, then we would expect a greater degree of disruption of 
cystogenesis by forms of Wrch-1 that are unable to become phosphorylated at Y254.  In 
agreement with this hypothesis, we found that constitutively phosphodeficient Wrch-
1(Y254F) disrupted epithelial cell morphogenesis, as shown by a greatly decreased 
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proportion of normal cysts containing a single lumen (Figure 2.5B), and this disruption was 
greater compared to the disruption induced by phosphorylatable Wrch-1, whether in a WT or 
in a constitutively GTP-bound and active (107L) background (Figure 5B).  Together, these 
data indicate a requirement for the Y254 residue for proper function of at least two important 
biological activities of Wrch-1, and suggest that tyrosine phosphorylation at this site may be 
an important mechanism to precisely control Wrch-1 activity. 
 
2.3.6 Wrch-1 interacts with its effector PAK at the plasma membrane, where it is GTP-
bound and active, but not at endosomes, where it is GDP-bound and inactive.   The 
lower biological activity displayed by wild type Wrch-1 compared to the phosphodeficient 
Wrch-1 mutant Y254F that was resistant to endosomal relocalization suggested that Wrch-1 
is less able to interact with its effectors when it is endosomally localized than when it is 
localized to the plasma membrane.  We therefore evaluated the ability of Wrch-1 to interact 
with its best-validated effector PAK at each of these locations, by utilizing a GFP-tagged 
form of the GTPase-binding domain of PAK (“GFP-PAK-PBD”).  If our hypothesis was 
correct, then the same conditions of serum stimulation that cause Wrch-1 to become 
phosphorylated at Y254 and to relocalize away from the plasma membrane should also 
decrease its interactions with PAK-PBD.  To test this, we cotransfected H1299 cells with 
GFP-PAK-PBD and HA-tagged Wrch-1 and observed their localization under conditions of 
serum starvation or stimulation. In serum-starved cells, Wrch-1 localized to both plasma 
membrane and endosomes, as expected (Figure 2.6A, red), and PAK-PBD (green) 
displayed overlapping localization with Wrch-1 (merge, yellow) at the plasma membrane.  
Upon serum stimulation, Wrch-1 redistributed away from the plasma membrane in a time-
dependent manner, such that by 15 min it was absent from the plasma membrane and 
localized predominantly to endosomes.  Under these conditions, PAK-PBD was distributed 
diffusely throughout the cell, and was recruited neither to plasma membrane nor to internal 
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membranes, consistent with our hypothesis that tyrosine phosphorylation and relocalization 
of Wrch-1 decreases its ability to interact with effectors.   
 
Because PAK-PBD binds preferentially to the active, GTP-bound form of Wrch-1, these 
results indicate that Wrch-1 is active at the plasma membrane but not at internal 
membranes.  To confirm that Wrch-1 would still be able to bind PAK-PBD at internal 
membranes if it were active and GTP-bound, we examined the ability of a constitutively 
activated, GAP-insensitive mutant of Wrch-1(Q107L) to recruit PAK-PBD.  As expected, the 
107L mutant still relocalized to endosomes upon serum stimulation, and still recruited PAK-
PBD even to internal membranes (Figure 2.6A).  Thus, the inability of WT Wrch-1 to recruit 
PAK-PBD following serum stimulation is not because PAK-PBD is simply unable to access 
the endosomal compartment or interact with tyrosine phosphorylated Wrch-1. 
 
Our observation that Wrch-1 recruited PAK-PBD to the plasma membrane but not to internal 
membranes further supports our hypothesis that tyrosine phosphorylation at Y254 and 
subsequent internalization downregulates Wrch-1 activity.  To further test this possibility, we 
examined recruitment of PAK-PBD by the nonphosphorylatable mutant Wrch-1(Y254F), 
which remains trapped on the plasma membrane and fails to relocalize in response to 
serum. Consistent with our hypothesis, the Y254F mutant continued to recruit PAK-PBD to 
the plasma membrane after serum stimulation even in the absence of a concurrent 
constitutively activating mutation 107L (Figure 2.6A).  This result indicates that the failure of 
Y254F to become internalized is sufficient to abrogate C-terminal phosphorylation-mediated 
downregulation of Wrch-1 activity and to retain Wrch-1 in an active conformation. 
  
Finally, if phosphorylation of Wrch-1 at Y254 is sufficient for relocalization to endosomes 
and subsequent downregulation of Wrch-1 activity and effector interaction, then a 
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phosphomimetic mutation should impair plasma membrane binding, and instead confer 
constitutive localization to endosomes and poor effector interaction.  Consistent with this, we 
observed that a phosphomimetic Y254E mutant was indeed largely excluded from the 
plasma membrane, localized to endosomes, and failed to recruit PAK-PBD unless also 
constitutively GTP-bound by virtue of a concurrent 107L mutation.  These results also 
corroborate the evidence suggesting that localization regulates Wrch-1 GTP-binding status, 
and that effector interaction of tyrosine phosphorylated Wrch-1 is impaired as a 
consequence of decreased GTP-binding rather than of decreased access to effector pools. 
 
In order to confirm these results biochemically, we performed pulldown assays to detect 
active Wrch-1-GTP.  Like GFP-tagged PAK-PBD, GST-tagged PAK-PBD also binds 
preferentially to active, GTP-bound Wrch-1, but subcellular localization plays no part in their 
interaction in the pulldown assay.  We cotransfected H1299 cells with empty vector or 
vectors expressing HA-tagged Wrch-1 proteins, and then either serum starved or starved 
and stimulated the cells with serum for 2, 5 or 15 min, exactly as for the GFP-PAK-PBD 
localization assays.  Cells were then lysed and incubated for 1 h with purified GST or GST-
PAK-PBD coupled to glutathione-agarose beads.  The resulting protein complex was pulled 
down by centrifugation, washed, eluted off the beads, resolved by SDS-PAGE, and 
immunoblotted for the active, GTP-bound HA-Wrch-1 that was pulled down by interaction 
with GST-PAK-PBD.   GST alone pulled down no Wrch-1 (data not shown), nor did GST-
PAK-PBD pull down anything detectable by anti-HA antibody in the absence of HA-Wrch-1 
(Figure 6B, vector).  As predicted by the recruitment of GFP-PAK-PBD, we found that prior 
to serum stimulation GST-PAK-PBD pulled down Wrch-1 quite strongly when Wrch-1 was 
able to localize to the plasma membrane (WT and Y254F) but pulled down almost none of 
the Wrch-1 expected to be excluded from the plasma membrane (Y254E) (Figure 2.6B).  
Also as predicted by GFP-PAK-PBD, the same conditions of serum stimulation that resulted 
 56 
in tyrosine phosphorylation and subsequent loss of plasma membrane binding and 
relocalization to endosomes also conferred decreased interaction with GST-PAK-PBD.  
Thus, by 5 min of serum stimulation, GST-PAK-PBD still pulled down Y254F robustly but the 
amount of WT Wrch-1 pulled down was dramatically decreased (Figure 2.6B).  Taken 
together, these results suggest that serum stimulation of phosphorylation of Wrch-1 at Y254 
causes its translocation from plasma membrane to endosomes where it is inactivated, 
presumably through the activity of a yet-unidentified GAP.  
 
2.3.7 Serum-stimulated tyrosine phosphorylation and relocalization of Wrch-1 
decreases its activation of downstream effectors in a Y254-dependent manner.   The 
decrease in Wrch-1/PAK effector interaction seen upon serum-stimulated tyrosine 
phosphorylation and subsequent relocalization of Wrch-1 to endosomes strongly implies that 
Wrch-1 activates this effector preferentially at the plasma membrane, and that internalization 
impairs effector activation.  We next wished to determine whether relocalization to 
endosomes decreased not only effector interaction but also effector activation.  However, 
PAK-PBD contains the GTPase binding domain but is not the full length PAK kinase effector 
of Wrch-1.  Further, it was not yet clear from the previous experiments whether the 
decreased active Wrch-1-GTP affects PAK alone or other effectors as well.  Active Wrch-1 
has been shown to stimulate autophosphorylation and activation of both the serine/threonine 
kinase PAK1 (Tao et al., 2001) and the non-receptor tyrosine kinase Pyk2 (Ruusala and 
Aspenstrom, 2008).   Therefore, we tested whether the same conditions that relocalized 
Wrch-1 and decreased active Wrch-1-GTP also altered the ability of these two kinases that 
are immediate downstream effectors of Wrch-1 to become activated.  Immunoblot analysis 
shows robust phosphorylation at the autophosphorylation sites of both PAK (Figure 2.7A) 
and Pyk2 (Figure 2.7B) in the presence of Wrch-1 WT or Y254F but not Y254E prior to 
serum stimulation, consistent with their interactions with PAK-PBD.  Indeed, levels of both 
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phospho-PAK1 and -Pyk2 were markedly decreased in the presence of phosphomimetic 
Wrch-1 (Y254E) and did not change regardless of serum stimulation.  Similarly, serum 
decreased autophosphorylation of PAK and PYK2 in the presence of WT Wrch-1, whereas 
Y254F conferred resistance to the decrease (Figure 2.7). Taken together, our results 
indicate that serum stimulation induces tyrosine phosphorylation of the membrane targeting 
region of Wrch-1 and its subsequent relocalization to endosomes, where it is rendered GDP-
bound and inactive, thereby decreasing effector interaction and activation.  These results 
are consistent with a model in which C-terminal tyrosine phosphorylation downregulates 
Wrch-1 activity, presumably by bringing it into proximity with an endosomally localized GAP. 
 
2.4 Discussion 
We show here that the atypical Rho family small GTPase, Wrch-1, undergoes serum-
stimulated Src-mediated tyrosine phosphorylation at residue Y254 in its C-terminal 
membrane targeting domain, a modification that dynamically alters its subcellular 
localization by promoting relocalization from the plasma membrane to endosomes.  We also 
show that Y254 is the major site of phosphorylation, and that mutation of Y254 to a 
nonphosphorylatable phenylalanine residue (Y254F) prevents relocalization, remains GTP-
bound, enhances recruitment of GTPase binding domain of the Wrch-1 effector PAK1 (PAK-
PBD) and enhances Wrch-1-mediated effects on growth transformation and on epithelial 
morphogenesis in 3D culture.  In contrast, both serum-stimulated WT Wrch-1 and 
phosphomimetic Y254E are restricted from the plasma membrane and are inactive, failing to 
recruit PAK-PBD or to activate the effector kinases PAK or Pyk2 unless mutationally 
activated to be GAP-insensitive (Q107L).  These results indicate that C-terminal tyrosine 
phosphorylation of Wrch-1 may be important for downregulation of its biological activities, 
and provide evidence supporting a mechanism whereby a novel endosomally localized 
Wrch-1 GAP turns off previously active Wrch-1-GTP. 
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Our results demonstrate that Wrch-1 is GTP-bound and active at the plasma membrane, 
where it is capable of interacting with and activating downstream effectors such as PAK1 
and Pyk2, but inactive at endosomal membranes, where it relocalizes following serum-
stimulated, Src-dependent phosphorylation at Y254.  That the GAP-insensitive mutant 
Q107L remains capable of effector interaction at endosomes even when targeted there by a 
C-terminal phosphomimetic mutation, Y254, indicates that phosphorylation-mediated 
relocalization to endosomes does not decrease Wrch-1 effector activation simply by 
removing Wrch-1 from its relevant effectors, at least some of which are still present at 
endosomes.   For example, the well-validated Wrch-1 effector PAK is not only present at 
endosomes but is recruited and activated preferentially there by Chp/Wrch-2 in response to 
TNFalpha (Chenette et al., 2005).  Instead, our results support a model in which  endosomal 
relocalization of Wrch-1 promotes its deactivation by enhancing its interaction with a novel 
endosomally localized GAP  The numbers of known GAPs capable of accelerating GTP 
hydrolysis on Rho family proteins already far exceeds the numbers of GTPases themselves, 
leading to speculation that the reason for the existence of multiple GAPs is to serve as 
location-specific downregulators of Rho family GTPase function.  While GAPs for Wrch-1 
are thought to exist, none has yet been identified.   Endosomal GAPs such as p50RhoGAP 
(Sirokmany et al., 2006) and ARAP1 (Daniele et al., 2008; Yoon et al., 2008) have been 
identified for other Rho family GTPases but are not known to promote GTP hydrolysis on 
Wrch-1. Other mechanisms of endosomal translocation and subsequent deactivation are 
well-documented for receptor tyrosine kinases (RTKs).  Upon autophosphorylation and 
activation following growth factor stimulation, many RTKs become ubiquitinated and 
undergo relocalization to the endosomal compartment, which attenuates their signaling 
(Dikic, 2003; Dikic and Giordano, 2003).  Additionally, ubiquitination of the small GTPase H-
Ras has been shown to promote its endosomal trafficking and thereby to attenuate its 
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signaling through the Raf-MEK-ERK pathway (Jura et al., 2006).  We have observed that 
Wrch-1 is also ubiquitinated but that this modification does not appear to alter either its 
localization or its biological activity (data not shown). Thus, our present data best support 
the model of C-terminal phosphorylation of Wrch-1 leading to its downregulation by 
enhancing proximity to one or more GAPs. 
 
Accumulating evidence suggests that phosphorylation of the C-terminal membrane targeting 
domains on small GTPases combines with other sequences and posttranslational 
modifications to dynamically regulate the localization and function of these proteins.  To 
date, all the phosphorylation sites so identified, whether in Ras or Rho GTPases, have been 
Ser/Thr residues just upstream of C-terminal farnesyl or geranylgeranyl isoprenoid 
modifications (Bivona, 2006 #84; Lerosey, 1991 #165; Lim KH, 2009 #172; Lang, 1996 #41; 
Ellerbroek, 2003 #154; Riento, 2005 #149; Okada, 2008 #159; Madigan, 2009 #435). 
However, the atypical Rho family GTPase Wrch-1 is neither modified by isoprenylation nor 
possesses cognate serine or threonine residues.  Instead, our study provides the first report 
of direct regulation of Rho family GTPase subcellular localization and function by tyrosine 
phosphorylation of its membrane targeting domain.  Although Cdc42 has been reported to 
be tyrosine phosphorylated by Src upon EGF stimulation (Tu et al., 2003), this 
phosphorylation occurs at residue Y64 within its switch II region rather than in the Cdc42 C-
terminus, which lacks any tyrosine residue. Whether tyrosine phosphorylation of Cdc42 
alters its subcellular localization was not explored, but it was reported to promote binding of 
Cdc42 to RhoGDI.  However, Wrch-1 is not modified by an isoprenoid, a feature required for 
binding of RhoGDI (Takai et al., 1995), and does not interact with RhoGDI (Berzat et al., 
2005a).  Thus, tyrosine phosphorylation of Wrch-1 and Cdc42 occur on distinct domains and 
have distinct consequences.  Chp/Wrch-2, the closest relative of Wrch-1, is also 
palmitoylated and unprenylated (Chenette et al., 2005), but, like Cdc42, Chp lacks a tyrosine 
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residue near its C-terminus.  This is perhaps not entirely surprising, as many closely related 
isoforms of small GTPases differ from each other mostly in their membrane targeting 
domains, possibly to provide signaling diversity. 
 
Wrch-1 tyrosine phosphorylation at Y254 occurs only two residues away from the critical 
palmitoylation site C256, raising the question of whether one modification sterically hinders 
the other.  It is clear that tyrosine phosphorylation of Wrch-1 does not require prior 
palmitoylation, as even a nonpalmitoylatable Cys>Ser mutant becomes tyrosine 
phosphorylated in the presence of Src (data not shown).  Although it is not yet known 
whether phosphorylation can occur simultaneously with palmitoylation, there is some 
indirect evidence that this is the case: we have shown here that tyrosine phosphorylation 
results in an increased association with internal membranes, whereas an inability to be 
palmitoylated results in a complete lack of Wrch-1 membrane association (Berzat et al., 
2005b).  Taken together, these results suggest that tyrosine phosphorylation normally 
occurs on palmitoylated Wrch-1. 
 
We have shown here that Wrch-1 tyrosine phosphorylation requires Src, and that Src can 
directly phosphorylate Wrch-1 in vitro.  Although Y254, the major residue for tyrosine 
phosphorylation, does not occur in the context of a known Src kinase consensus site, and 
algorithms such as NetPhos or ScanSite do not predict its phosphorylation by Src, there is 
currently no reliable predictor of whether a given protein is in fact a substrate for Src in vivo.  
Even enolase, a commonly used positive control for Src phosphorylation, does not contain a 
known Src consensus site.   However, many tyrosine kinases require phosphorylation 
themselves in order to be active, and this activating or priming phosphorylation step may be 
accomplished in cis or in trans.  Therefore, other than direct phosphorylation of Wrch-1 by 
Src, another possibility is that Src activity promotes binding to Wrch-1 and/or activation of 
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another tyrosine kinase that can phosphorylate it. Whether Wrch-1 is a direct or an indirect 
downstream target of Src-mediated phosphorylation in cells remains to be determined. 
 
Recent studies have suggested several context-dependent functional connections between 
Wrch-1 and Src that are likely to be pertinent regardless of whether the connection is direct 
or indirect. In osteoclasts, Wrch-1 colocalizes with Src in podosomes, and increased Wrch-1 
activity perturbs the podosome belt (Ory et al., 2007).  Thus, Src-mediated tyrosine 
phosphorylation of Wrch-1  could contribute to the dynamic regulation of podosome 
formation and assembly. In addition, Wrch-1 negatively regulates M-CSF-stimulated 
osteoclast migration (Brazier et al., 2009), and Src has recently been shown to be activated 
in osteoclasts downstream of M-CSF stimulation (Yano et al., 2008). Therefore, M-CSF may 
promote osteoclast migration by activating Src, to then downregulate Wrch-1 through 
tyrosine phosphorylation on Y254.  In contrast to osteoclasts, where it decreases migration, 
Wrch-1 increases the migration of fibroblasts (Chuang et al., 2007), where it is localized to 
focal adhesions (Ory et al., 2007) and regulates their assembly.  Src and several of its 
substrates are major components of focal adhesions.  In PAE cells, Wrch-1 but not Cdc42 
requires Src to induce filopodia formation (Ruusala and Aspenstrom, 2008), but it is 
unknown whether Src is required for an effect on Wrch-1 itself or on a downstream target 
not shared with Cdc42. 
 
We have observed that Y254, the major site of Src-mediated tyrosine phosphorylation, 
negatively regulates Wrch-1-mediated anchorage-independent growth and epithelial cell 
morphogenesis, because mutation to the nonphosphorylatable Y254F conferred greater 
activity on Wrch-1 than the wild type tyrosine residue.  Thus, Src-mediated tyrosine 
phosphorylation at Y254 may normally act as a brake for Wrch-1 function. Although Src is 
often thought of simply as an oncogene that leads inexorably to cellular de-differentiation, it 
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is clear that it can exert dual functions.  For example, Src serves dual functions during 
epithelial cell morphogenesis in Drosophila, where it both antagonizes E-cadherin-mediated 
cell adhesion and simultaneously stimulates E-cadherin transcription (Shindo et al., 2008).  
Similarly, if Src modulates Wrch-1 through opposing functions, then proper cycling between 
the phosphorylated and the unphosphorylated state of Wrch-1 is likely to be required for the 
correct final outcome, regardless of whether Wrch-1 is a direct or indirect target of Src 
kinase activity.  It will certainly also be of interest to determine which phosphatase(s) 
contribute to restoration of the unphosphorylated state of Wrch-1. 
 
Our observations identify important contributors to Wrch-1 regulation and lend further 
credence to the emerging paradigm that C-terminal phosphorylation of small GTPases may 
serve as key mechanism to dynamically regulate their localization, activation and function.  
Thus, further investigations into such phosphorylation events will be critical for a better 
understanding of the regulation of Rho GTPases.   
 
 
2.5 Materials and methods  
2.5.1 Molecular constructs 
Mammalian expression constructs for GFP-tagged and HA epitope-tagged human Wrch-1 
(WT and Q107L) have been described previously (Berzat et al., 2005b).  Phosphodeficient 
Wrch-1(Y254F) and phosphomimetic Wrch-1(Y254E) were generated by site-directed 
mutagenesis in both WT and Q107L backgrounds. The GFP-fusion protein of the C-terminal 
9 amino acids (“9 aa tail”) of Wrch-1 expressed from pEGFP has been described previously  
(Berzat et al., 2005b).  An additional GFP-fusion containing the C-terminal 19 amino acids 
(“19 aa tail”) was generated by site-directed mutagenesis in the same manner. All 
sequences were verified by the Genome Analysis Facility at UNC-CH.  GFP-PAK-PBD and 
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GST-PAK-PBD were kind gifts from Channing Der (UNC-CH) and Keith Burridge (UNC-CH), 
respectively.  WT Src, constitutively active Src(Y528F) and kinase-deficient Src(K297R) 
were expressed from the pUSE vector, all from Upstate Biotechnology.  Bacterial expression 
constructs and purification of GST-Wrch-1 protein have been described previously (Shutes 
et al., 2006). 
 
2.5.2 Cell culture, transfections, and retroviral infection 
H1299 nonsmall cell lung cancer (NSCLC) cells were grown in Dulbecco’s modified Eagle 
medium (high glucose) (DMEM-H, GIBCO/Invitrogen) supplemented with 10% fetal bovine 
serum (FBS, Sigma) and 1% penicillin-streptomycin (P/S) (“complete culture medium”), and 
maintained in 5% CO2 at 37°C.  H1299 cells were transfected with expression constructs 
encoding Wrch-1, Src, or PAK-PBD proteins by using TransIT-LT1 (Mirus) according to the 
manufacturer’s instructions.  For localization assays, cells were transfected transiently and 
used 24 h after transfection.  For selection of stably expressing cell lines, cells were grown 
in complete medium supplemented with the appropriate antibiotic for 5-7 days, after which 
>50 colonies were pooled for use. 
 
MDCKII cells, generously provided by Robert Nicholas (UNC-CH), were grown as above 
and supplemented with 1% non-essential amino acids (NEAA, Invitrogen) (“complete 
medium”). MDCKII cell lines stably expressing Wrch-1 were generated by retroviral infection.  
Retrovirus was collected following CaCl2-mediated transfection of pBabe-HAII-puro, 
pVPack-Gag/Pol, and pVPack-Ampho (Stratagene) expression vectors into 293T cells.  
Cells were infected by exposure to retroviral supernant containing 8 µg/ml of Polybrene 
(American Bioanalytical) and maintained in puromycin for 10 days, after which the colonies 
were pooled for use. 
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SYF mouse embryo fibroblast cells (MEFs) genetically lacking Src, Yes and Fyn, or YF cells 
lacking Yes and Fyn but retaining Src (Klinghoffer et al., 1999), were grown in complete 
culture medium as above.  Cells were transiently transfected with constructs encoding HA-
Wrch-1 proteins by using TransIT-LT1 (Mirus) according to the manufacturer’s instructions.. 
 
2.5.3 Fluorescence, immunofluorescence, confocal microscopy and localization 
assays 
Cells were transfected transiently with pEGFP-Wrch-1 expression vectors or pEGFP-PAK-
PBD as indicated above and grown in complete medium for 24 h.  The cells were then either 
grown further overnight in complete medium (“basal conditions”), or serum-starved overnight 
(“serum-starved”), or serum-starved overnight then stimulated for 2, 5, or 15 min. with fresh 
serum-containing complete medium (“starved + stimulated”). For some experiments, cells 
were treated for 1 h with the Src family kinase inhibitor, SU6656 (Sigma), or DMSO vehicle 
prior to serum stimulation.  Following incubation with Alexa 647-transferrin (Molecular 
Probes), cells were fixed and then visualized for GFP-Wrch-1 (green) or transferrin (red). 
HA-Wrch-1 was visualized by staining with a primary anti-HA antibody (Covance) and a 
secondary anti-mouse antibody conjugated to Alexa 647 (Invitrogen). Confocal microscopy 
was performed on an Olympus Fluoview 500 laser scanning confocal imaging system, 
configured with an IX81 fluorescence microscope fitted with a PlanApo X60 oil objective.   
 
2.5.4 Antibodies and western blot analysis  
Western blot analyses were carried out as described previously (Brady et al., 2009).  Briefly, 
cells were lysed in Magnesium Lysis Buffer (MLB) containing 1X protease inhibitor cocktail 
(Roche) with or without 100 µM pervanadate, lysates were cleared by centrifugation and 
protein concentrations determined using the DC Lowry protein assay (BIO-RAD). Twenty µg 
of protein for each sample, prepared in 5X Laemmli sample buffer, were resolved by using 
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12% SDS-PAGE.  Proteins were transferred to polyvinylidene difluoride membranes (PVDF, 
Millipore), blocked overnight in 3% fish gelatin, then probed for Wrch-1 by a 1 h incubation 
with the following primary antibodies: anti-HA epitope (HA.11, Covance), anti-
phosphotyrosine (pY100, Cell Signaling Technologies (CST), and pY20, Santa Cruz),  anti-
GFP (JL8, Clontech), anti-PAK1/2/3 (CST), anti-phospho-PAK1(Thr423)/-PAK2(Thr402) 
(CST), anti-Pyk2 (Yu et al., 1996), or anti-phospho-Pyk2(Tyr402) (Biosource). Anti-β-actin 
(Sigma) was used to demonstrate equivalent loading. Washed membranes were incubated 
in anti-mouse or anti-rabbit IgG-HRP (Amersham Biosciences) or anti-mouse kappa light 
chain-HRP (Zymed), washed again, and developed using SuperSignal West Dura extended 
duration substrate (Pierce).    
 
2.5.5 Immunoprecipitation  
H1299 cells expressing GFP- or HA-tagged Wrch-1 were lysed in MLB with protease 
inhibitor, with or without pervanadate, as described above, at 24 h after transfection. Lysates 
were pre-cleared with Protein A/G beads (Santa Cruz) and then incubated overnight with 
anti-GFP or anti-HA antibody. After 18 h, the protein-antibody complex was recovered using 
Protein A/G beads. Beads were collected and washed with MLB and resuspended in 
Laemmli sample buffer, the precipitated proteins were resolved on SDS-PAGE, and 
immunoblot analysis for phosphotyrosine was performed as described above.    
 
2.5.6 In vitro tyrosine kinase assay 
Recombinant Wrch-1 protein was used as a substrate for purified Src kinase in a standard in 
vitro kinase assay. Bacterially expressed GST-Wrch, GST alone, or 1 mg  recombinant enolase 
protein (Calbiochem) to serve as a standard positive control were incubated for 40 min at 30°C 
with or without 0.8 mg of purified recombinant Src protein (Upstate Biotechnology) in Src Kinase 
Reaction Buffer (100 mM Tris, pH 7.2; 125 mM MgCl2, 25 mM MnCl2, 2 mM EGTA, 100 mM 
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Na3VO4, and 2 mM DTT) containing [g-32P]ATP (10 mCi per reaction).  Reactions were 
terminated by the addition of 4X sample buffer and then heated at 95°C for 5 min.  Protein 
samples were separated on 10% SDS-PAGE and visualized by Coomassie blue staining.  
Incorporation of radiolabel was determined by audioradiography. 
 
2.5.7 Anchorage-independent growth transformation assay 
Single cell suspensions of MDCK cells (3.5 x 103 cells per 35-mm dish) were suspended in 
0.4% agar (BD Biosciences) in complete medium and layered on top of 0.6% agar as 
described previously (Brady et al., 2009). After 14 days, colonies were stained with 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma) after counting of small 
(6-15 cell diameters) and large (>15 cell diameters) colonies, and the average number of 
each type of colony on triplicate dishes was quantified. A one-way ANOVA and Tukey's 
post-hoc test were performed; p values of <0.01 were considered significant. 
 
2.5.8 Epithelial morphogenesis cyst formation assay 
MDCKII cells stably expressing HA-tagged Wrch-1 proteins were allowed to form cysts in 3D 
collagen matrices as described previously (Brady et al., 2009).  Briefly, monodispersed 
MDCKII cells were allowed to grow and form cyst structures on collagen I gels for 10 days, 
when the cultures were treated with collagenase type VII (Sigma C-2399).  Cyst structures 
were fixed and permeabilized, then incubated with fluorescent Texas-Red phalloidin 
(Molecular Probes) and mounted for imaging on an Olympus Fluoview confocal microscope 
as indicated above.  Multiple XY and XZ scans were acquired for each 3D collagen gel.  We 
have shown previously that tightly regulated endogenous Wrch-1 activity is critical for proper 
cystogenesis on 3D collagen I matrices in these cells (Brady et al., 2009). 
 
2.5.9 Wrch-1 activation assay 
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H1299 cells were transiently transfected with either pCGN vector only, or pCGN vectors 
encoding HA-Wrch-1, HA-Wrch-1(Y254F), HA-Wrch-1(Y254E), HA-Wrch-1(Q107L), HA-
Wrch-1(Q107L/Y254F) or HA-Wrch-1(Q107L/Y254E), by using Transit LT1 as described 
above. Cells were serum-starved overnight, or serum-starved, and then serum-stimulated 
for 2, 5 or 15 min as described above. Cells were then washed twice with ice-cold PBS (pH 
7.4) and lysed in MLB as described above.  Equal volumes were removed from each lysate 
for total protein analysis. To each lysate, glutathione-agarose beads containing 40 µg of 
GST-p21-activated kinase (PAK) GTPase binding domain fusion protein (GST-PAK-PBD) 
was added and incubated at 4°C for 60 min with rocking. Agarose-GST-PAK-PBD and 
associated Wrch-1 was pelleted and washed three times with 500 µL wash buffer [25 
mmol/L Tris (pH 7.5), 40 mmol/L sodium chloride, and 30 mmol/L magnesium chloride]. 
Final pellets were resuspended in 1X protein sample buffer and resolved on SDS-PAGE. 
HA-Wrch-1 was detected using anti-HA antibody (Covance). 
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Figure 2.1 Wrch-1 rapidly relocalizes to endosomal compartments upon serum 
stimulation. H1299 NSCLC cells expressing GFP-Wrch-1 were grown in complete culture 
medium, then serum-starved overnight, or first serum-starved and then serum-stimulated.  
Prior to serum-stimulation, the treated cells were incubated for 1 h with Alexafluor 647-
labeled transferrin to mark endosomal compartments. After 15 min of serum-stimulation, 
cells were fixed, then subjected to confocal microscopy for  visualization of GFP-Wrch-1 
(green) or transferrin (red). 
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Figure 2.2A  Wrch-1 is tyrosine phosphorylated on Y254 in response to serum, 
and this phosphorylation is required for serum-stimulated relocalization. A) 
Serum-stimulated tyrosine phosphorylation of Y254. H1299 cells expressing either 
GFP-Wrch-1 or GFP-Wrch-1(Y254F) were grown, treated and evaluated as in Figure 1. 
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Figure 2.2B  Wrch-1 is tyrosine phosphorylated on Y254 in response to serum, and 
this phosphorylation is required for serum-stimulated relocalization. B) Non-
phosphorylatable Wrch-1(Y254F) is resistant to serum-stimulated relocalization. H1299 cell 
lysates from cells expressing empty vector, HA-Wrch-1 or HA-Wrch-1(Y254F) were 
incubated with anti-HA antibody. Immunoprecipitated (IP) Wrch-1 was detected by 
immunoblotting (IB) with anti-HA, and phosphotyrosine (p-Tyr) on Wrch-1 was detected by 
immunoblotting with anti-phosphotyrosine antibody. The bands above and below the Wrch-
1 band represent immunoglobulin heavy chain and light chain, respectively. 
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Figure 2.3A  The C-terminal 19 amino acids of Wrch-1 are sufficient to become tyrosine 
phosphorylated and to relocalize in response to serum. A) Schematic of 19 aa and 9 aa 
tails. Shown are the sequences of GFP extended with 9 or 19 amino acids (aa) of the C-
terminus of Wrch-1.  Y254 is the only tyrosine residue present in each fusion protein.  B) 
Serum-stimulated tyrosine phosphorylation of the C-terminal 19 but not 9 amino acids of Wrch-
1. H1299 cell lysates expressing either empty vector, GFP-Wrch-1, GFP fused to the last 19 
amino acids of Wrch-1 (19 aa tail) or GFP fused to the last 9 amino acids of Wrch-1 (9 aa tail) 
were incubated with anti-GFP antibody to immunoprecipitate Wrch-1.  Wrch-1 was then 
detected by immunoblotting with anti-GFP antibody, and phosphotyrosine Wrch-1 was 
detected by immunoblotting with anti-phosphotyrosine antibody. 
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Figure 2.3B  The C-terminal 19 amino acids of Wrch-1 are sufficient to become 
tyrosine phosphorylated and to relocalize in response to serum. C) The C-terminal 19 
amino acids of Wrch-1 are sufficient for serum-stimulated relocalization. H1299 cells as in 
Panel B were grown in complete culture medium, then serum-starved overnight, or first 
serum-starved and then serum-stimulated for 15 min. The treated cells were incubated with 
Alexafluor 647-transferrin to mark endosomal compartments as in Figure 1, fixed, then 
visualized using confocal microscopy to detect GFP-Wrch-1 (green) or transferrin (red). 
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Figure 2.4A  Src activity is required in vivo for tyrosine phosphorylation of Wrch-1. 
A) The Src family tyrosine kinase inhibitor SU6656 prevents Wrch-1 tyrosine phosphorylation 
in response to serum stimulation. H1299 cells expressing HA-Wrch-1 were serum-starved 
overnight. Cells were then treated with 5 µM SU6656 for 1 h, and serum-stimulated for 5 min. 
Lysates of these cells were subjected to immunoprecipitation with anti-HA to retrieve HA-Wrch-
1, following by detection of Wrch-1 (anti-HA) or phosphotyrosine (anti-p-Tyr). The bands above 
and below the Wrch-1 band represent immunoglobulin heavy chain and light chain, 
respectively. B) Endogenous Src is required for serum-stimulated Wrch-1 tyrosine 
phosphorylation. SYF -/- MEFs (MEFs lacking Src, Yes, and Fyn) and YF -/- MEFs (MEFs 
retaining Src but lacking Yes and Fyn) expressing either HA-Wrch-1 or non-phosphorylatable 
HA-Wrch-1(Y254F) were serum-starved overnight, then serum-stimulated for 5 min.  The 
resulting cell lysates were probed for phosphotyrosine on Wrch-1 as in Panel A. The bands 
above and below the Wrch-1 band represent immunoglobulin heavy chain and light chain, 
respectively. 
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Figure 2.4A  Src activity is required in vivo for tyrosine phosphorylation of Wrch-1. 
C) Src kinase activity is required for tyrosine phosphorylation of Wrch-1. H1299 cells were 
co-transfected with empty vector, HA-Wrch-1 or nonphosphorylatable HA-Wrch-1(Y254F) 
along with either empty vector, kinase-active Src (Src Y528F) or kinase-deficient Src (Src 
K297R). The resulting cell lysates were probed for phosphotyrosine on Wrch-1 as in Panel 
A. The bands above and below the Wrch-1 band represent immunoglobulin heavy chain 
and light chain, respectively. D) Src directly phosphorylates Wrch-1 in vitro. Purified 
recombinant GST-Wrch-1 protein was incubated with purified recombinant Src tyrosine 
kinase protein and 32P-ATP.  Total protein was detected by Coomassie blue staining and 
32P-ATP incorporation was detected by autoradiography. 
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Figure 2.4C  Src activity is required in vivo for tyrosine phosphorylation of Wrch-1. 
E) Inhibition of Src kinase with SU6656 blocks serum-stimulated relocalization of Wrch-1. 
H1299 cells expressing GFP-Wrch-1 or nonphosphorylatable GFP-Wrch-1(Y254F) were 
grown in complete culture medium (basal), then either serum-starved overnight (serum-
starved), first serum-starved and then serum-stimulated for 15 min, or starved overnight then 
pretreated with 5 µM SU6656 for 1 h prior to serum stimulation for 15 min. The treated cells 
were incubated with Alexafluor 647-transferrin as in Figure 2.1, fixed and visualized by 
confocal microscopy for Wrch-1 (green)  or transferrin . 
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Figure 2.5A  Phosphorylation at Y254 negatively regulates Wrch-1-mediated biological 
functions.A) Phosphorylatable tyrosine residue Y254 negatively regulates anchorage-
independent growth.  MDCKII cell lines were generated to stably express either vector only, 
HA-Wrch-1, HA-Wrch-1(Y254F), HA-Wrch-1(107L) or HA-Wrch-1(107L/Y254F). Equivalent 
expression was confirmed by immunoblotting with anti-HA. β-actin was used as a loading 
control.  Cells were then seeded into soft agar and colonies were allowed to grow in an 
anchorage-independent manner for 14 days. Colonies were stained with MTT and the 
numbers of small (6-15 cell diameters across) and large (>15 cell diameters across) colonies 
were quantified.  Bar graphs are representative of three independent experiments carried out 
in triplicate.  A one-way ANOVA and Tukey's post-hoc test were done to determine 
significance of differences between numbers of colonies arising from cells expressing Wrch-1 
with or without the Y254F mutation, in both the WT and constitutively activated (107L) 
backgrounds.  Double asterisks (**) indicate a p value of <0.001. 
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Figure 2.5B  Phosphorylation at Y254 negatively regulates Wrch-1-mediated biological 
functions. B) Phosphorylatable tyrosine residue Y254 negatively regulates epithelial cell 
morphogenesis. MDCKII cells expressing Wrch-1 as in Panel A were seeded into 3D 
collagen matrices and allowed to form cysts for 10 days.  Cyst structures were evaluated and 
quantified according to whether they contained one lumen (“normal", "single lumen"), more 
than one lumenal area (“multi-lumen”), or no lumen at all (“no lumen”).  Bars represent the 
average of three independent experiments for each cell line, +/- SEM. A one-way ANOVA 
and Tukey's post-hoc test were done to determine significance of differences between 
numbers of normal cysts with single lumens in cells expressing Wrch-1 with or without the 
Y254F mutation, in both the WT and constitutively activated (107L) backgrounds.  Asterisks 
(*) denote a p value of <0.01. 
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Figure 2.6A Wrch-1 is GTP-bound and active, and recruits its effector PAK1, at 
plasma membrane but not at endosomes.  A) Serum stimulation decreases Wrch-1 
recruitment of GFP-PAK-PBD to the plasma membrane. H1299 cells co-expressing GFP-
PAK-PBD along with HA-tagged WT, phosphodeficient Y254F or phosphomimetic Y254E 
Wrch-1 mutants in either a WT or a GAP-insensitive (107L) background were grown in 
complete culture medium, then serum-starved overnight, or first serum-starved and then 
serum-stimulated for either 2, 5 or 15 m. After serum stimulation, cells were fixed and then 
stained for HA-Wrch-1 with a primary anti-HA antibody, and a secondary anti-mouse 
antibody conjugated to Alexa-647. The cells were then subjected to confocal microscopy 
for  visualization of GFP-PAK-PBD (green) or HA-Wrch-1 (red). Overlapping localization 
(merge, yellow) demonstrates recruitment of GFP-PAK-PBD by Wrch-1. 
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Figure 2.6A Wrch-1 is GTP-bound and active, and recruits its effector PAK1, at 
plasma membrane but not at endosomes.  A) Serum stimulation decreases Wrch-1 
recruitment of GFP-PAK-PBD to the plasma membrane. H1299 cells co-expressing GFP-
PAK-PBD along with HA-tagged WT, phosphodeficient Y254F or phosphomimetic Y254E 
Wrch-1 mutants in either a WT or a GAP-insensitive (107L) background were grown in 
complete culture medium, then serum-starved overnight, or first serum-starved and then 
serum-stimulated for either 2, 5 or 15 m. After serum stimulation, cells were fixed and 
then stained for HA-Wrch-1 with a primary anti-HA antibody, and a secondary anti-mouse 
antibody conjugated to Alexa-647. The cells were then subjected to confocal microscopy 
for  visualization of GFP-PAK-PBD (green) or HA-Wrch (red).  Overlapping localization 
(merge, yellow) demonstrates recruitment of GFP-PAK-PBD by Wrch-1. 
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Figure 2.6B Wrch-1 is GTP-bound and active, and recruits its effector PAK1, at 
plasma membrane but not at endosomes.  B) Serum stimulation decreases active 
Wrch-1-GTP as shown by pulldown assay with GST-PAK-PBD. To pull down active 
Wrch-1-GTP with GST-PAK-PBD, H1299 cells were transiently transfected with either 
pCGN-HA empty vector, or pCGN vector expressing HA-tagged Wrch-1 proteins, and 
treated as in Panel A. Resulting cell lysates were incubated with GST-p21-activated 
kinase (PAK) fusion protein attached to glutathione-agarose beads.  The resulting Wrch-
1/GST-PAK-PBD complex was collected by centrifugation, washed, eluted from the 
beads and resolved by SDS-PAGE. Wrch-1 was detected by immunoblot analysis using 
anti-HA antibody.  Upper panels:  pulldown followed by immunoblot, representing Wrch-
1-GTP; lower panels:  immunoblot of input, representing total Wrch-1 available for 
pulldown in that sample.  
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Figure 2.7 Serum-stimulated Wrch-1 tyrosine phosphorylation and endosomal 
relocalization results in decreased Wrch-1 effector activation.  A) Serum stimulation 
results in decreased autophosphorylation of PAK1. H1299 cells expressing HA-tagged forms 
of the indicated Wrch-1 proteins were treated as described in the legend to Figure 6.  Total 
PAK was detected by immunoblotting with an anti-PAK1/2/3 antibody and active, phospho-
PAK was detected using an anti-phospho(Thr423)-PAK1/phospho(Thr402)-Pak2 antibody.  
Signal was quantitated by densitometry, phospho-protein was normalized to normal protein, 
then compared to no serum conditions, which was set to 100%. B) Serum stimulation results 
in decreased Pyk2 autophosphorylation. H1299 cells expressing HA-tagged forms of the 
indicated Wrch-1 proteins were treated and analyzed as in Panel A, except that total Pyk2 
was detected by immunoblotting with anti-Pyk2 antibody and phospho-Pyk2 was detected 
with anti-phospho(Tyr402)-Pyk2 antibody.  Quantitation was done as indicated in Panel A. 
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CHAPTER III 
 
REGULATION OF MEMBRANE TRAFFICKING AND BIOLOGICAL ACTIVITIES OF THE 
RHO FAMILY SMALL GTPASE WRCH-1, BY THE TYROSINE KINASES EGFR AND SRC 
 
 
3.1 Abstract 
 
Wrch-1 is an atypical Rho family small GTPase with roles in oncogenic transformation, 
epithelial cell morphogenesis, osteoclastogensis, and migration. Wrch-1 membrane 
localization and biological functions are modulated by reversible addition of the fatty acid 
palmitate at its C-terminal membrane targeting domain. Additionally, have shown that 
localization of Wrch-1 is modulated by Src-mediated tyrosine phosphorylation in the C-
terminal membrane-targeting region; after serum stimulation, Wrch-1 becomes tyrosine 
phosphorylated at Y254, and then relocalizes to endosomal compartments.  Although we 
have shown that Wrch-1 tyrosine phosphorylation at Y254 is Src dependent, other upstream 
signals and kinases involved were previously unknown.   We observed that Wrch-1 was 
tyrosine phosphorylated in response to EGF treatment in a dose and time dependent 
manner, and this phosphorylation can be blocked by treatment with EGFR inhibitors. We 
also observed rapid relocalization of Wrch-1 from the plasma membrane to endosomes 
upon EGF stimulation, similar to the relocalization that occurs after serum stimulation.  
Additionally Wrch-1 is tyrosine phosphorylated at Y254 downstream of constitutively active 
EGFR and HER2 receptors, including EGFRvIII, a deletion mutant found in many 
glioblastomas, breast cancers, etc (Kuan, 2001 #133; Huang, 2007 #136). We speculated 
that Wrch-1 tyrosine phosphorylation downstream of EGFR may be Src dependent. Indeed, 
EGF stimulated Wrch-1 tyrosine phosphorylation was blocked in the presence of the Src 
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family kinase inhibitor SU6656.  Wrch-1 tyrosine phosphorylation downstream of EGFR 
maybe be facilitated by Cbl binding, and subsequently acting as an adaptor, as we found 
that Wrch-1 binding to Cbl increased after serum stimulation.  Functionally, the 
phosphodeficient mutant Y254F was enhanced in Wrch-1-mediated migration. Thus, EGFR-
mediated, Src dependent C-terminal tyrosine phosphorylation of Wrch-1 may represent a 
mechanism to regulate trafficking and biological outcomes of Wrch-1.  C-terminal tyrosine 
phosphorylation represents a new paradigm in posttranslational control of small GTPase 
localization and biological function.    
 
3.2 Introduction 
  
Rho family proteins are Ras-related small GTPases that are known for their role in 
regulating cytoskeleton organization and dynamics, cell adhesion, motility, trafficking, 
proliferation and survival (Jaffe and Hall, 2005).  Rho GTPases are tightly regulated 
molecular switches that cycle between the active GTP-bound state and the inactive GDP-
bound state, with additional positive regulation by GEFs (guanine nucleotide exchange 
factors) and negative regulation by GAPs (GTPase accelerating proteins).  In addition to 
nucleotide status, Rho GTPases are also regulated by their subcellular localization, which is 
directed by sequences and post-translational modifications within their C-terminal 
membrane targeting domains.  Most Rho GTPases are post-translationally modified by an 
isoprenoid lipid irreversibly attached to the C-terminal CAAX motif (Adamson et al., 1992), 
and an additional second signal, which usually consists of a polybasic region or a palmitate 
fatty acid upstream of the CAAX motif (Michaelson et al., 2001; Williams, 2003).   As an 
additional level of control, Rho GTPases can also be regulated by their interactions with 
RhoGDIs (Rho-guanine nucleotide dissociation inhibitors) that bind their prenyl groups and 
sequester the GTPases in the cytosol, rendering them inactive (Isomura et al., 1991; Takai 
et al., 1995).   
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Wrch-1, also designated RhoU or Wrch1 (Brazier et al., 2006; Kirikoshi and Katoh, 2002; 
Tao et al., 2001), is an atypical member of the Cdc42 subgroup of Rho GTPases. Like other 
members of the Cdc42 subgroup, Wrch-1 also induces the formation of actin microspikes 
and filopodia.  Wrch-1 shares 57% sequence identity with Cdc42 and 61% sequence identity 
with its closest relative, Chp/Wrch-2, as well as partially overlapping localization and effector 
interactions.  Activation of Wrch-1 leads to activation of PAK1 (Tao, 2001 #79), JNK 
(Chuang, 2007 #125), and Pyk2 (Ruusala, 2008 #134), to formation of filopodia (Ruusala 
and Aspenstrom, 2008; Saras et al., 2004), and to both morphological (Brady et al., 2009) 
and growth transformation (Berzat et al., 2005a; Brady et al., 2009). Wrch-1 also regulates 
focal adhesion turnover (Chuang et al., 2007; Ory et al., 2007), cell migration (Chuang et al., 
2007), negatively regulates the kinetics of tight junction formation (Brady et al., 2009), plays 
a required role in epithelial cell morphogenesis (Brady et al., 2009), and modulates 
osteoclastogenesis (Brazier et al., 2009; Ory et al., 2007).   
 
Wrch-1 was initially discovered as a Wnt-responsive gene that was capable of 
phenocopying Wnt morphological transformation in mouse mammary epithelial cells when 
mutationally activated (Taneyhill and Pennica, 2004; Tao et al., 2001).  In addition to 
transcriptional upregulation by Wnt signaling, Wrch-1 is also transcriptionally upregulated in 
in MEFs a JNK-dependent manner (Schiavone et al., 2009) and in bone marrow 
macrophages during osteoclastogenesis upon RANKL stimulation (Brazier et al., 2006). 
Recently Wrch-1 expression has also been shown to be responsive to gp130-class 
cytokines, which transcriptionally regulate Wrch-1 expression via STAT3 (Schiavone et al., 
2009).  Furthermore, it has been shown that Wrch-1 expression varies dramatically in 
different cancer types. The expression of Wrch-1 is upregulated in some tumor types but 
downregulated in others (Kirikoshi and Katoh, 2002).  Taken together, these data imply that 
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modulation of Wrch-1 expression is a common regulatory event, and that a proper level of 
Wrch-1 expression and perhaps activity is required.   Because Wrch-1 is a GTP-binding 
protein, more dynamic regulation of its activity is also required, in addition to transcriptional 
regulation.   
 
We have shown previously that phosphorylation of Wrch-1 at Y254 regulates its subcellular 
localization. In response to serum stimulation, this phosphorylation results in Wrch-1 
relocalization from the plasma membrane to endomembranes.  When it is located at the 
plasma membrane, Wrch-1 is GTP-bound and capable of inducing activation of at least two 
of its effectors, PAK1 and Pyk2.  However, once it relocalizes to endomembranes, it 
becomes GDP-bound, and its activation of PAK1 and Pyk2 decreases.  Additionally, a 
phosphomimetic mutant of Wrch-1 is localized constitutively to endomembranes (Y254E) 
and exhibits decreased anchorage-independent growth, whereas a phosphodeficient mutant 
is chronically localized to the plasma membrane (Y254F) and is enhanced in the same 
biological readout.  
 
The pattern of growth factor-stimulated Wrch-1 relocalization suggests that there may be a 
specific trafficking mechanism regulating Wrch-1, similar to that regulating RTKs such as 
EGFR.  There are several examples of Cdc42 family members that are involved intracellular 
trafficking.  Cdc42 shares high sequence similarity with two other members of the Cdc42 
family, TC10 and TCL.  Like Cdc42, TC10 promotes the formation of filopodia, activates 
JNK, and promotes SRF- and NF-κB-mediated transcription (Murphy et al., 1999).  TCL 
promotes the formation of membrane ruffles and lamellipodia (Aspenstrom et al., 2004; 
Vignal et al., 2000).  Interestingly, somewhat similarly to Wrch-1 TC10 localizes mainly to 
the plasma membrane and intracellular membranes, whereas TCL localizes to endosomes. 
TC10 localization and biological function are dependent on posttranslational modifications in 
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its C-terminal hypervariable membrane targeting region.  These modifications include 
isoprenylation of its CAAX motif and palmitoylation of an upstream cysteine.  TC10 is 
phosphorylated by CDK5 on Thr197 in its C-terminal hypervariable region.  Phosphorylation 
at Thr197 by CDK mediates the association of TC10 with lipid rafts, which modulates its 
ability to mediate insulin-stimulated GLUT4 translocation (Okada et al., 2008). TCL localizes 
mostly to endosomes, has been previously shown to associate with early endosomes, and is 
also able to regulate the transfer of transferrin from early endosomes to recycling 
endosomes (de Toledo et al., 2003).  A proper balance of TCL activity is required for this 
function, because both loss of TCL and constitutive activation of TCL restrict transferrin to 
early endosomes (de Toledo et al., 2003). Like most Rho GTPases, both the C-terminal 
membrane targeting domain and proper localization are crucial for TCL function, because 
the fusion of C-terminal sequences of TCL to either Cdc42 or TC10 had a similar effect on 
transferrin trafficking (de Toledo et al., 2003).  These studies further highlight the importance 
of localization in regulating the function of family proteins. Wrch-1 localizes to the plasma 
membrane and internal membranes, and its localization and function is regulated by C-
terminal phosphorylation. 
 
In the present study, we sought to determine the role of EGF-stimulated tyrosine 
phosphorylation of Wrch-1, and the role that Wrch-1 plays in intracellular trafficking.  Our 
previous study determined that serum stimulation resulted in Wrch-1 phosphorylation on 
Y254, which then regulated Wrch-1 subcellular localization, activation and function.  Further 
research was needed to elucidate the component(s) in serum responsible for tyrosine 
phosphorylation and subsequent regulation of Wrch-1 function. Additionally, further research 
was needed to understand the mechanisms controlling Wrch-1 trafficking, and the 
subsequent biological consequences.  In this report we describe our discovery that EGF 
stimulates tyrosine phosphorylation of Wrch-1 in a dose- and time-dependent manner, and 
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that Src is required for this event.  We also report that Wrch-1 tyrosine phosphorylation is 
important in regulating some EGFR-driven biological functions, including migration and 
invasion. 
 
3.3 Results 
 
 
3.3.1 Wrch-1 is tyrosine phosphorylated in response to stimulation with EGF and 
PDGF but not bradykinin or LPA.  We have shown previously that Wrch-1 is tyrosine 
phosphorylated in response to cell stimulation with serum, which contains a myriad of 
proteins and growth factors.  In order to determine which component of serum was 
responsible for Wrch-1 tyrosine phosphorylation, we screened a panel of ligands known to 
be present in serum.   We serum-starved overnight H1299 NSCLC cells transiently 
transfected with HA-Wrch-1, and then stimulated them with a panel of ligands.  We then 
immunoprecipitated the Wrch-1 with an anti-HA antibody, followed by western blotting using 
an anti-phosphotyrosine antibody to probe for phosphotyrosine Wrch-1. We observed that 
Wrch-1 was tyrosine phosphorylated in response to RTK ligands such as EGF and PDGF, 
but not ligands for GPCRs such as bradykinin, a key activator of Cdc42 (Kozma et al., 1995) 
or LPA, a major stimulatory component of serum (Figure 3.1A and data not shown).   We 
found that tyrosine phosphorylation of Wrch-1 required at least 30 ng of EGF (Figure 3.1B) 
suggesting that it may occur under conditions of aberrant EGFR signaling. In order to 
determine the kinetics of the response, we stimulated cells with 30 ng of EGF for 0, 5, 15, 
30, or 60 min. We found that Wrch-1 tyrosine phosphorylation in response to EGF occurred 
as early as 10 min, and was sustained for up to 60 min (Figure 3.1C), suggesting that this 
phosphorylation is induced by continuous and sustained EGFR stimulation.  EGF stimulation 
can activate both EGFR homodimers and EGFR/HER2 heterodimers. In order to determine 
the specificity of EGF stimulation in our system, we serum-starved cells expressing HA-
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Wrch-1 and then treated with 30 ng EGF in the presence or absence of an EGFR-selective 
inhibitor (erlotinib) or a dual EGFR/HER2 inhibitor (lapatinib). We found that EGF-stimulated 
tyrosine phosphorylation of Wrch-1 was abolished in the presence of either erlotinib or 
lapatinib (Figure 3.1D).  Wrch-1 may thus be phosphorylated in response to EGF through 
either EGFR homodimers or EGFR/HER2 heterodimers.  Finally, in order to determine if 
Wrch-1 could be tyrosine phosphorylated in the presence of mutant EGFR or HER2 
receptors, we examined Wrch-1 tyrosine phosphorylation in the presence of constitutively 
activated EGFR (EGFRvIII) and HER2 (NeuT) receptors. We co-transfected H1299 cells 
with HA-Wrch-1 and either EGFRvIII or NeuT, immunoprecipitated HA-Wrch-1 and blotted 
as described above.   We found that, in the presence of these constitutively activated EGFR 
family members, Wrch-1 was tyrosine phosphorylated in the absence of outside stimulus 
(Figure 3.1E), indicating that Wrch-1 can be tyrosine phosphorylated in response to the 
expression of constitutively active EGFR and HER2 receptors.     
 
3.3.2 Wrch-1 tyrosine phosphorylation in response to EGF is Src-dependent.  
Previously we had determined that both Src expression and kinase activity were required for 
Wrch-1 tyrosine phosphorylation in response to serum stimulation.  In order to determine 
whether Src was also required for Wrch-1 phosphorylation in response to EGF stimulation, 
we serum-starved H1299 cells expressing HA-Wrch-1 then stimulated the cells with EGF in 
the presence or absence of the Src family kinase inhibitor SU6656.  We observed that in the 
presence of SU6656, EGF stimulation was not sufficient to induce tyrosine phosphorylation 
of Wrch-1 (Figure 3.2), suggesting that Src family kinase activity is required downstream of 
EGF stimulation to phosphorylate Wrch-1.  
  
3.3.3 EGF stimulation causes Wrch-1 to traffic to endosomal compartments. We had 
previously determined that, upon serum stimulation, Wrch-1 trafficks from the plasma 
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membrane to internal membranes.  Since EGF stimulation, like serum stimulation, results in 
tyrosine phosphorylation of Wrch-1, we sought to determine whether it also caused 
subsequent trafficking of Wrch-1 from the plasma membrane to internal membranes.  In 
order to do this, we transiently transfected H1299 cells with GFP-Wrch-1, then serum-
starved the cells overnight before stimulating with EGF.  We then labeled the cells with 
Alexa 647-transferrin, fixed them with paraformaldehyde, and imaged them using an 
Olympus IX-81 confocal microscope.  We observed that, like serum, EGF stimulation 
resulted in the relocalization of Wrch-1 from the plasma to internal membranes  (Figure 3.3).   
These data suggest that Wrch-1 may undergo trafficking in response to EGF-stimulated 
phosphorylation, in a similar way to trafficking of EGFR. 
 
3.3.4 EGF stimulation causes Wrch-1 to traffick to early endosomes, recycling 
endosomes and lysosomes.   When we treated cells expressing Wrch-1 with EGF, we saw 
a relocalization similar to that of EGFR, suggesting that Wrch-1 may utilize a similar 
trafficking pathway. When EGFR undergoes internalization in response to EGF stimulation, 
it trafficks to early endosomes, and then both to recycling endosomes, which recycle EGFR 
back to the plasma membrane, and also to lysosomes, which degrade EGFR.  In order to 
determine whether Wrch-1 trafficked in a similar fashion to EGFR, we sought to determine 
the endosomal compartment(s) to which Wrch-1 localizes after EGF stimulation. To do this, 
we stimulated H1299 cells expressing GFP-Wrch-1 with EGF as described above. We then 
either pre-incubated the cells with Lysotracker-red to label lysosomes, or co-stained with 
markers for early endosomes (EEA1) or recycling endosomes (Rab 11). We found that, after 
EGF stimulation, Wrch-1 localized to early endosomes to a small extent, along with 
recycling endosomes and lysosomes. These data indicate that, like EGFR, a portion of 
internalized Wrch-1 may be recycled back to the plasma membrane via recycling 
endosomes, and another portion of Wrch-1 may be degraded by the lysosomes (Figure 3.4).  
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3.3.5 EGF stimulation causes Wrch-1 to traffick to endosomal compartments with Src. 
We observed that Wrch-1 trafficking to endomembranes was similar to the pattern of EGFR 
trafficking after ligand stimulation.  We hypothesized that Wrch-1 may also co-traffick with 
proteins known to traffick with EGFR, such as Src.  To test this hypothesis, we transfected 
H1299 cells with GFP-Wrch-1, then serum-starved the cells and stimulated with EGF.  We 
then fixed the cells and co-stained for Src, and visualized the cells as described above.  We 
found that Wrch-1 did co-localize with Src at internal membranes after EGF stimulation, 
suggesting that Wrch-1 may traffick with components of the EGFR complex (Figure 3.5).   
 
3.3.6 Tyrosine phosphorylation of Wrch-1 on Y254 negatively regulates migration and 
invasion. It is well accepted that Rho proteins are regulated in part by their subcellular 
localization.  In line with this, we found that phosphorylation of Y254 that induces 
relocalization of Wrch-1 to the endosomes subsequently resulted in a decrease in active 
Wrch-1-GTP.  We have shown previously that this relocalization and change in nucleotide 
status regulated specific biological events driven by Wrch-1, such as growth in soft agar and 
epithelial morphogenesis. Here we sought to determine whether C-terminal tyrosine 
phosphorylation of Wrch-1 also regulates EGF-driven properties also known to be 
modulated by Wrch-1, such as cell migration and/or invasion.  To determine whether 
tyrosine phosphorylation of Wrch-1 regulated cell migration, we performed a scratch assay 
using H1299 cells stably expressing Wrch-1, and a nonphosphorylatable version of Wrch-1 
(Y254F). We found that cells expressing Wrch-1(Y254F) more completely closed the scratch 
compared to cells expressing parental Wrch-1 (Figure 3.6A). Finally, we sought to determine 
whether this phosphorylation regulates Wrch-1-mediated invasion. To do this we analyzed 
the same cell lines in a Matrigel invasion assay.  We found that nonphosphorylatable Wrch-
1 [Wrch-1(Y254F)] increased Matrigel invasion, compared to parental Wrch-1 (Figure 3.6B).  
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Taken together with our previous studies, these data suggest that phosphorylation of Wrch-
1 at Y254 may be a general mechanism for negative regulation of Wrch-1-mediated 
biological activities.  
 
3.4 Discussion 
We show here that the atypical Rho family small GTPase Wrch-1 undergoes tyrosine 
phosphorylation at a key residue in its membrane targeting domain in response to EGF 
stimulation and downstream of constitutively active EGFR family tyrosine kinases.  Our 
previous work on phosphorylation of Wrch-1 showed that Src expression and kinase activity 
was required for Wrch-1 tyrosine phosphorylation at Y254 in the C-terminal hypervariable 
region.  In this follow-up study, we show that phosphorylation of this residue downstream of 
EGFR family members regulates trafficking of Wrch-1 from the plasma membrane to internal 
membranes.  Additionally we show that Src is required for EGFR-mediated tyrosine 
phosphorylation of Wrch-1 at this key residue that is important for both localization and 
biological activity.   
 
Our previous study showed that Wrch-1 is GTP-bound and active at the plasma membrane 
where it is capable of interacting with and activating downstream effectors such as PAK1 
and Pyk2, but inactive at endosomal membranes, where it localizes following both serum 
and EGF stimulation.  Consistent with this hypothesis, plasma membrane-localized Wrch-
1(Y254F) is enhanced in both migration and Matrigel invasion, whereas endosomally 
localized Wrch-1(Y254E) is impaired in the same biological outputs.   
 
Our data suggest that Wrch-1 may undergo a trafficking mechanism for downregulation 
somewhat similar to RTKs. Upon persistent growth factor stimulation, RTKs such as EGFR 
under go ubiquitination and internalization to internal compartments where they are either 
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degraded or recycled to the plasma membrane. We have shown that when Wrch-1 becomes 
re-localized to endosomes, it becomes GDP-bound and inactive.   In this study we show that 
upon growth factor stimulation, Wrch-1 relocalizes from the plasma membrane to internal 
membranes including early endosomes, recycling endosomes, and lysosomes. This 
suggests that in addition to being turned off at the endosomes,  Wrch-1 may recycle back to 
the plasma membrane to become activated, and some portion of Wrch-1 may be degraded.. 
Further studies are needed to determine whether Wrch-1 expression is altered in response 
to growth factor stimulation.     
 
This is the first report that receptor tyrosine kinase stimulation results in phosphorylation and 
translocation of a Rho small GTPase. Although Cdc42 has been reported to be tyrosine 
phosphorylated by Src upon EGF stimulation, this phosphorylation occurs at residue Y64 
within its switch II region rather than in the C-terminus of Cdc42, which lacks any tyrosine 
residue  (Tu et al., 2003). Whether tyrosine phosphorylation of Cdc42 alters its subcellular 
localization was not explored, but it was reported to promote binding of Cdc42 to RhoGDI 
(Wu et al., 2003).  However, Wrch-1 is not modified by an isoprenoid lipid, a feature required 
for binding of RhoGDI, and does not interact with RhoGDI (Berzat et al., 2005a).  Thus, 
tyrosine phosphorylation of Wrch-1 and Cdc42 occur on distinct domains and have distinct 
consequences.  
 
EGFR is known to activate small GTPases, such as Ras and RhoA.  Classically, after EGFR 
activation, the Grb2/Sos complex promotes Ras GTP-binding and activation of the 
Raf/MEK/ERK kinase cascade to promote biological outcomes such as cellular proliferation 
(Roskoski, 2004). Furthermore, it has been shown that EGFR activation can promote 
increased RhoA activity, leading to an increase in RhoA-driven cell motility (Mateus et al., 
2007).  Additionally, in NSCLC cells, EGFR has been shown to upregulate Rac1 activity via 
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Vav2, resulting in an increased invasive phenotype (Marcoux and Vuori, 2003; Patel et al., 
2007).  Currently there are no known examples of negative regulation of a small GTPase by 
EGFR.  However, there is some evidence that tyrosine kinases can negatively regulate Rho 
GTPase activity. Loss of FAK in epithelial cells promoted loss of epithelial cell morphology 
and inhibited cell-cell contacts, which was blocked by expression of dominant negative 
versions of Rho and Rac (Playford et al., 2008).   Inhibition of FAK decreased tyrosine 
phosphorylation of p190RhoGAP and increased Rho and Rac GTP levels (Playford et al., 
2008). 
 
In this work, we have shown that EGFR is an upstream mediator of Wrch-1 tyrosine 
phosphorylation, and that this phosphorylation regulates Wrch-1-mediated migration.  
Although beyond the scope of this paper, there is also the possibility that tyrosine 
phosphorylation of Wrch-1 may also regulate EGFR expression or signaling.  In this paper, 
we have shown that Wrch-1 binds to Cbl in a tyrosine phosphorylation-dependent manner. 
Cdcc42 also binds to Cbl, and been shown to sequester Cbl and increase abundance of 
EGFR.   Cdc42 binds to p85Cool-1 (Cloned-out-of-library)/β-Pix (Pak interacting exchange 
factor), which is a protein that directly associates directly with c-Cbl (Wu et al., 2003).  The 
association of p85Cool-1/β-Pix with c-Cbl prevents EGFR ubiquitination by Cbl, therefore 
reducing destruction of EGFR, resulting in higher levels of EGFR protein.  Activated Cdc42 
was shown to block Cbl from binding to EGFR, which increased EGFR expression, 
sustained ERK activation and increased transformation (Wu et al., 2003).  Currently, it is not 
known whether Wrch-1 interaction with Cbl results in the same phenomenon, and whether 
an intermediary protein such as p85Cool-1/β-Pix is required.  Further studies aimed at 
addressing the role of Wrch-1 in modulating RTK signaling pathways will give us further 
insight into overall Wrch-1 effector pathways and biological function, and may shed light on 
general Rho GTPase regulation with respect to RTK signaling. 
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3.5 Materials and methods 
3.5.1 Molecular constructs   
Mammalian expression constructs for GFP-tagged and HA epitope-tagged human Wrch-
(WT and Q107L) have been described previously (Berzat et al., 2005b).  Phosphodeficient 
Wrch-1(Y254F) was generated by site-directed mutagenesis in both WT and Q107L 
backgrounds. All sequences were verified by the UNC-CH Genome Analysis Facility at the 
University of North Carolina at Chapel Hill. EGFRvIII and NeuT constructs were generous 
gifts from H. Shelton Earp (UNC-CH). 
 
3.5.2 Cell culture and transfections 
H1299 nonsmall cell lung cancer (NSCLC) cells were grown in Dulbecco’s modified Eagle 
medium (high glucose) (DMEM-H, GIBCO/Invitrogen) supplemented with 10% fetal bovine 
serum (FBS, Sigma) and 1% penicillin-streptomycin (P/S) (“complete culture medium”), and 
maintained in 5% CO2 at 37°C.  H1299 cells were transfected with expression constructs 
encoding Wrch-1, EGFRvIII, or NeuT proteins by using TransIT-LT1 (Mirus) according to the 
manufacturer’s instructions.  For localization assays, cells were transfected transiently and 
used 24 h after transfection.  For selection of stably expressing cell lines, cells were grown 
in complete medium supplemented with the appropriate antibiotic for 5-7 days, after which 
>50  colonies were pooled for use.  
 
3.5.3 Fluorescence, immunofluorescence, confocal microscopy and localization 
assays  
Cells were transfected transiently with pEGFP-Wrch-1 expression vectors as indicated 
above and grown in complete medium for 24 h.  The cells were then either grown overnight 
in complete medium (“basal conditions”), or serum-starved overnight (“serum- starved”), or 
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serum-starved overnight then stimulated with complete medium containing varying 
concentrations of EGF (“starved + stimulated”). For some experiments, cells were treated for 
1 h with the EGFR-selective inhibitor erlotinib, the dual EGFR/HER2 inhibitor lapatinib, or 
DMSO vehicle prior to serum stimulation.  Following incubation with Alexa 647-transferrin  
(Molecular Probes) or Lysotracker-red (Invitrogen), cells were fixed and then visualized for 
GFP-Wrch-1 (green), transferrin (red), or Lysotracker (red). HA-Wrch-1 was visualized by 
staining with a primary anti-HA antibody (Covance) and a secondary anti-mouse antibody 
conjugated to Alexa 647 (Invitrogen). Src was visualized using an anti-Src antibody (Cell 
Signaling Technologies (CST)), and a secondary anti-rabbit antibody conjugated to Alexa 
594 (Invitrogen). Early endosomes were visualized using an anti-EEA1 antibody (Abcam) 
and Rab 11 was visualized using an anti-Rab 11 antibody (BD Biosciences). Both were 
followed by incubation with anti-mouse antibody conjugated to Alexa 647 (Invitrogen). 
Confocal microscopy was performed on an Olympus Fluoview 500 laser scanning confocal 
imaging system, configured with an IX81 fluorescence microscope fitted with a PlanApo X60 
oil objective.    
  
3.5.4 Antibodies and western blot analysis   
Western blot analyses were carried out as described previously (Brady et al., 2009).  Briefly, 
cells were lysed in Magnesium Lysis Buffer (MLB) containing 1X protease inhibitor cocktail 
(Roche) with 100 µM pervanadate, lysates were cleared by centrifugation and protein 
concentrations  determined using the DC Lowry protein assay (BIO-RAD). Twenty µg of 
protein for each sample, prepared in 5X Laemmli sample buffer, were resolved by using 
12% SDS-PAGE.  Proteins were transferred to polyvinylidene difluoride membranes (PVDF, 
Millipore), blocked overnight in 3% fish gelatin, then probed for Wrch-1 by a 1 h incubation 
with the following primary antibodies: anti-HA epitope (HA.11, Covance), anti-
phosphotyrosine (pY100, (CST), and pY20, Santa Cruz), anti-EGFR (CST), or anti-Src 
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(CST).  Anti-actin (Sigma) was used to demonstrate equivalent loading. Washed 
membranes were incubated in anti-mouse or anti-rabbit IgG-HRP (Amersham Biosciences) 
or anti-mouse kappa light chain-HRP (Zymed), washed again, and developed using 
SuperSignal West Dura extended duration substrate (Pierce).     
 
3.5.5 Immunoprecipitation   
H1299 cells expressing HA-tagged Wrch-1 were lysed in MLB with protease inhibitor with 
pervanadate, as described above, at 24 h after transfection. Lysates were pre-cleared with 
Protein A/G beads (Santa Cruz) and then incubated overnight with an anti- HA antibody. 
After 18 h, the protein-antibody complex was recovered using Protein A/G beads. Beads 
were collected and washed with MLB and resuspended in Laemmli sample buffer, the 
precipitated proteins were resolved on SDS-PAGE, and immunoblot analysis for 
phosphotyrosine was performed as described above.     
 
3.5.6 Scratch assays for cell motility 
H1299 cells stably expressing HA-tagged Wrch-1 constructs were allowed to grow to 
confluency in a standard 35 mm tissue culture dish.  A scratch wound was then made in the 
confluent monolayer by using a disposable P20-200 pipet tip, and any debris was washed 
away twice with PBS and once with media.  The wound was imaged immediately after 
scratching and 24 h later.  
 
3.5.7 Matrigel invasion assays 
H1299 cells stably expressing HA-tagged Wrch-1 were plated on Matrigel in serum-free 
culture medium in the top chamber of a Matrigel multiwell assay plate (BD Biosciences) 
(50,000 cells per well). Cells were allowed to invade through the Matrigel and migrate to the 
bottom chamber, which contained 10% FBS. After 24 h, cells in the bottom chamber were 
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then fixed in 100% methanol, stained with 1% bromphenol blue, and quantified using a light 
microscope fitted with a 20x objective.   
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Figure 3.1A Wrch-1 is tyrosine phosphorylated in response to EGF or PDGF 
stimulation but not bradykinin.  A) Wrch-1 is tyrosine phosphorylated upon EGF or 
PDGF stimulation. H1299 NSCLC cells expressing HA-Wrch-1 were serum-starved 
overnight and treated with either 10% FBS, 30 ng EGF, 100 ng PDGF, or 30 ng 
bradykinin for 30 min.  The resulting cell lysates were incubated with anti-HA antibody. 
Immunoprecipitated (IP) Wrch-1 was detected by immunoblotting (IB) with anti-HA, and 
phosphotyrosine (p-Tyr)  Wrch-1 was detected by immunoblotting with anti-
phosphotyrosine antibody. The bands above and below the Wrch-1 band represent 
immunoglobulin heavy chain and light chain, respectively. B) Wrch-1 is tyrosine 
phosphorylated in response to EGF stimulation in a dose-dependent manner. H1299 
cells expressing HA-Wrch-1 were serum starved overnight and treated with increasing 
concentrations of EGF, up to 100 ng for 30 min.  The resulting cell lysates were 
incubated with anti-HA antibody. Immunoprecipitated (IP) Wrch-1 was detected by 
immunoblotting (IB) with anti-HA, and phosphotyrosine (p-Tyr)  Wrch-1 was detected by 
immunoblotting with anti-phosphotyrosine antibody. The bands above and below the 
Wrch-1 band represent immunoglobulin heavy chain and light chain, respectively.  C) 
Wrch-1 is tyrosine phosphorylated in response to EGF stimulation in a time dependent 
manner. H1299 cells expressing HA-Wrch-1 were serum-starved overnight and treated 
with 30 ng EGF for increasing amounts of time, up to 60 min.  The resulting cell lysates 
were incubated with anti-HA antibody. Immunoprecipitated (IP) Wrch-1 was detected by 
immunoblotting (IB) with anti-HA, and phosphotyrosine (p-Tyr) Wrch-1 was detected by 
immunoblotting with anti-phosphotyrosine antibody. The bands above and below the 
Wrch-1 band represent immunoglobulin heavy chain and light chain, respectively. 
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Figure 3.1  Wrch-1 is tyrosine phosphorylated in response to EGF or PDGF 
stimulation but not bradykinin. D) EGF stimulated tyrosine phosphorylation of Wrch-
1 can be blocked by both and EGFR and a dual EGFR/HER2 inhibitor. H1299 cells 
expressing HA-Wrch-1 were serum starved overnight and treated with 30 ng EGF in the 
presence of either 10 µM lapatinib or 1.5 µM erlotinib.  The resulting cell lysates were 
incubated with anti-HA antibody. Immunoprecipitated (IP) Wrch-1 was detected by 
immunoblotting (IB) with anti-HA, and phosphotyrosine (p-Tyr)  Wrch-1 was detected by 
immunoblotting with anti-phosphotyrosine antibody. The bands above and below the 
Wrch-1 band represent immunoglobulin heavy chain and light chain, respectively. E) 
Wrch-1 is tyrosine phosphorylated downstream of constitutively active EGFR family 
members. H1299 cells expressing HA-Wrch-1 plus either empty vector, EGFRvIII or 
NeuT were lysed.  The resulting cell lysates were incubated with anti-HA antibody. 
Immunoprecipitated (IP) Wrch-1 was detected by immunoblotting (IB) with anti-HA, and 
phosphotyrosine (p-Tyr) Wrch-1 was detected by immunoblotting with anti-
phosphotyrosine antibody. The bands above and below the Wrch-1 band represent 
immunoglobulin heavy chain and light chain, respectively. 
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Figure 3.2 Wrch-1 tyrosine phosphorylation in response to EGF is Src dependent. 
H1299 cells  expressing HA-Wrch-1 were serum-starved overnight and treated with 30 
ng EGF for 30 min in the presence or absence of 5 µM SU6656.  The resulting cell 
lysates were incubated with anti-HA antibody. Immunoprecipitated (IP) Wrch-1 was 
detected by immunoblotting (IB) with anti-HA, and phosphotyrosine (p-Tyr)  Wrch-1 was 
detected by immunoblotting with anti-phosphotyrosine antibody. The bands above and 
below the Wrch-1 band represent immunoglobulin heavy chain and light chain, 
respectively. 
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Figure 3.3 EGF stimulation causes Wrch-1 to traffick to endosomal 
compartments. H1299 cells expressing GFP-Wrch-1 were grown in complete 
culture medium, then serum-starved overnight, or first serum-starved overnight and 
stimulated with 30 ng EGF.  Prior to EGF stimulation, the treated cells were 
incubated for 1 h with Alexafluor 647-labeled transferrin to mark endosomal 
compartments. After 30 min of EGF stimulation, cells were fixed, then subjected to 
confocal microscopy for visualization of GFP-Wrch-1 (green) or transferrin (red). 
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Figure 3.4 EGF stimulation causes Wrch-1 to traffick to early endosomes, 
recycling endosomes and lysosomes.  H1299 cells expressing GFP-Wrch-1 
were grown in complete culture medium, then serum-starved overnight, or first 
serum-starved overnight and stimulated with 30 ng EGF. Prior to EGF stimulation, 
the treated cells were incubated for 1 h with Lysotracker-red to mark lysosomes. 
After 30 min of EGF stimulation, cells were fixed, stained with EEA1 or Rab 11 then 
subjected to confocal microscopy for visualization of GFP-Wrch-1 (green) or EEA1 
(red), Rab 11 (red), or Lysotracker (red) . 
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Figure 3.5 EGF stimulation causes Wrch-1 to traffic to endosomal 
compartments with Src. H1299 cells expressing GFP-Wrch-1 were grown in 
complete culture medium, then serum-starved overnight, or first serum-starved 
overnight and stimulated with 30 ng EGF. After 30 min of EGF stimulation, cells 
were fixed, stained with anti-Src, then subjected to confocal microscopy for 
visualization of GFP-Wrch-1 (green) or Src (red). 
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Figure 3.6 Tyrosine phosphorylation of Wrch-1 on Y254 negatively regulates 
migration and invasion. A) Phosphorylatable tyrosine residue Y254 negatively 
regulates migration.  H1299 cell lines were generated to stably express either vector 
only, HA-Wrch-1(107L) or HA-Wrch-1(107L/Y254F). Cells were allowed to grow to 
confluency, and were then scratched with a P200 disposable pipet tip.  Cells were 
visualized at time 0 and also 24 h later. B) Phosphorylatable tyrosine residue Y254 
negatively regulates Matrigel invasion.  H1299 cell lines were generated to stably 
express either vector only, HA-Wrch-1(107L), or HA-Wrch-1(107L/Y254F).  Fifty 
thousand cells were plated into the top chamber in 0% serum, and allowed to migrate 
for 24 h toward the bottom chamber containing 10% serum.  Cells were then fixed in 
100% methanol and stained with 1% bromophenol blue. The number of cells that 
migrated through the Matrigel was quantified using a light microscope with a 20x 
objective, and represented as fold over vector. A two-tailed t-test was done to 
determine significance of differences between the cell lines. 
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CHAPTER IV 
 
SUMMARY AND FUTURE DIRECTIONS 
 
 
 
4.1 Summary 
 
My research on Wrch-1 has uncovered a novel mechanism of post-translational control of 
Wrch-1 localization and function.  As discussed previously, phosphorylation of the 
membrane targeting domains of Rho proteins is emerging as a general mechanism to 
control their localization and function. Currently, most of the research regarding this type of 
phosphorylation of Rho proteins has focused on Ser/Thr phosphorylation (Okada, 2008 
#159; Lang, 1996 #41; Forget, 2002 #140; Riento, 2005 #149; Madigan, 2009 #435).  To 
date there is one report of tyrosine phosphorylation of a Rho family protein. Cdc42 was 
shown to be tyrosine phosphorylated, but in the switch II region, and this phosphorylation 
resulted in decreased Cdc42 activation by altering RhoGDI binding (Tu et al., 2003).  My 
dissertation research has provided the first report of C-terminal tyrosine phosphorylation as 
a mechanism for controlling proper localization and function of Rho family small GTPases.   
 
I have shown here that serum and growth factor stimulation results in an increase in C-
terminal phosphorylation on Y254 of Wrch-1, which then results in relocalization of Wrch-1 
from the plasma membrane to endosomes.  Upstream receptor tyrosine kinases (RTKs) 
involved in this phosphorylation event include EGFR, PDGFR, and Src. Currently it is not 
known whether other growth factors in serum such as HGF, IGF, NGF, etc., can also induce 
tyrosine phosphorylation of Wrch-1.  After relocalization to endosomes, Wrch-1 becomes 
GDP-bound, and activation of two of its effectors, PAK1 and Pyk2, is decreased.  It would 
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be interesting to determine whether activation of other Wrch-1 effectors, such as Par6, 
PLCγ, and PI3K, is also altered.  I have shown here that Wrch-1-mediated biological 
endpoints such as migration, Matrigel invasion, anchorage-independent growth, and 
epithelial cell morphogenesis are all negatively regulated by phosphorylation of Wrch-1 at 
Y254.  It would also be interesting to examine other biological activities in which has been 
shown to play a role, such as osteoclastogenesis, cell:cell and cell: substrate adhesion, and 
cell cycle control.   
 
In this dissertation, I have shown that Wrch-1 can be tyrosine phosphorylated in response to 
EGF and PDGF stimulation.  However, I have neither characterized a role for Wrch-1 
phosphorylation in regulating signaling from EGFR or PDGFR, nor determined whether 
Wrch-1 is necessary for any of the biological activities driven by these receptors.  There is 
still more to discover about how Wrch-1 contributes to RTK signaling pathways. This line of 
inquiry may uncover novel signaling pathways and will contribute to our overall knowledge of 
these pathways.  
 
Although I have concentrated here on characterizing the role of C-terminal tyrosine 
phosphorylation in Wrch-1 localization, activation and function, there are additional C-
terminal post-translational modifications that can also contribute to Wrch-1 regulation.  For 
example, Wrch-1 is di-mono-ubiquitinated (as discussed below), and at least one of these 
ubiquitin molecules is incorporated into the C-terminal membrane-targeting region. Further 
characterization of this modification is needed, and may help lend insight into both Wrch-1 
and general Rho GTPase regulation.  In this chapter, I discuss four specific research 
directions that are logical extensions of my dissertation work and that may prove fruitful in 
the near future to enhance our understanding of Wrch-1 regulation and biological activity.   
 
 107 
4.2 Future Direction 1: Determine how PDGFR-mediated phosphorylation alters Wrch-
1 localization and function.  Over 20 years ago, it was shown that the transforming 
retroviral oncogene v-sis is derived from the β-chain of PDGFR (platelet-derived growth 
factor receptor), which highlighted the importance of PDGF signaling in carcinogenesis 
(Doolittle et al., 1983; Waterfield et al., 1983).  PDGFR is a receptor tyrosine kinase that is 
an important upstream regulator of cell proliferation, cellular differentiation, and cell growth 
and development (Andrae et al., 2008). Although PDGFR can elicit many of the same 
biological functions as EGFR, it has additionally been implicated in regulating tumor stromal 
fibroblasts and tumor angiogenesis. The PDGF family of ligands consists of PDGF-A, -B, -C, 
and -D which form either homo- or heterodimers  (PDGF-AA, -AB, -BB, -CC, -DD) (Bergsten 
et al., 2001; LaRochelle et al., 2001; Li et al., 2000). The best-studied PDGF ligands are 
PDGF-A and -B.  The four PDGFs are inactive in their monomeric forms, and are required to 
dimerize to form an active ligand. PDGF receptors consist of two isoforms, α and β (Figure 
4.1) (Johnsson et al., 1982).  Upon ligand binding, PDGFR subunits also dimerize in αα, ββ, 
or αβ combinations.  Once ligand-induced dimerization occurs, transphosphorylation and 
activation of the receptor ensues to elicit downstream signaling (Andrae et al., 2008; 
Kazlauskas and Cooper, 1989). The best characterized effectors of PDGFR include the 
Ras/mitogen-activated protein kinase (MAPK) (Zubiaur et al., 1996), PI-3 kinase 
(Kazlauskas and Cooper, 1990), STATs (Darnell, 1997), PLCγ (Kundra et al., 1994), and Src 
(Ralston and Bishop, 1985), along with the adaptor proteins Grb2 (Matuoka et al., 1993), 
Nck (Nishimura et al., 1993), Grb7 (Yokote et al., 1996), and Crk (Nishimura et al., 1993) 
(Figure 4.2). Although much remains to be learned about the regulation of PDGFR 
trafficking and endosomal signaling, PDGFR does undergo endosomal trafficking in a 
pattern similar to that of EGFR, and can elicit signaling from both the plasma membrane and 
endosomes (Wang et al., 2004).  In this dissertation I have shown that Wrch-1 is tyrosine 
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phosphorylated downstream of PDGF-ββ stimulation. Previously it was shown that Wrch-1 
binds the adaptor proteins Grb2 and Nckβ (Saras et al., 2004; Shutes et al., 2004)), both of 
which also bind PDGFR (Andrae et al., 2008; Bazenet et al., 1996). Interestingly, PDGF-ββ 
stimulation of cells reversed Wrch-1-induced cell rounding (Saras et al., 2004).  The authors 
hypothesized that PDGF signals to Rac1 to overcome the rounded phenotype, because 
activated Rac conferred a similar phenotype. However, reversion of Wrch-1-induced 
rounding after PDGF stimulation is also consistent with our model in which PDGF stimulates 
phosphorylation of Wrch-1 at Y254, which then re-localizes Wrch-1 to endosomes, where it 
becomes GDP-bound and inactive.  At present I have shown only that PDGF, like EGF, 
stimulates Wrch-1 tyrosine phosphorylation, but not whether this phosphorylation, like that 
mediated by EGF, also regulates trafficking of Wrch-1.  Additionally it is not known whether 
PDGFR can phosphorylate Wrch-1 directly, or whether an intermediary kinase such as Src 
is required for this phosphorylation.   Further investigation is needed to determine how 
phosphorylation of Wrch-1 downstream of PDGFR alters Wrch-1 localization and function. 
To test this, it will be important to first establish appropriate conditions for these assays.  I 
would first determine a dose response curve for PDGF-stimulated phosphorylation of Wrch-
1.  The specificity of the stimulation could also be examined by blocking with a PDGFR 
inhibitor, such as CP-673451, which has been shown to be an inhibitor of PDGFRβ (Roberts 
et al., 2005). Once the EC50 is determined for PDGF in our system, this dose can be used to 
stimulate cells for varying amounts of time, to determine the kinetics of Wrch-1 
phosphorylation by PDGFR. Additionally, it would be useful to determine which PDGFR 
dimer(s) are contributing to Wrch-1 tyrosine phosphorylation. This could be accomplished by 
either using specific PDGF ligand dimers, or by overexpressing, or knocking down specific 
PDGFR subunits in our system.    
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It would be of interest to determine whether Wrch-1 can modulate PDGFR-driven activities 
such as angiogenesis or fibrogenesis.  Anginogenesis could be evaluated in vitro using a 
tube formation assay, or in vivo using a zebrafish or mouse model system.  Fibrinogenesis 
could be evaluated in vitro using a hydroxyproline assay,which measures collagen content, 
or in vivo in a mouse model system by tissue harvesting and staining for fibrotic tissue, or by 
the hydroxyproline assay. If Wrch-1 does regulate angiogenesis or fibrogenesis, further 
investigation would be needed to determine whether phosphorylation of Wrch-1 by PDGFR 
is important for its contribution to these events.  In order to investigate this possibility, Wrch-
1 phosphodeficient (Y254F) or phosphomimetic (Y254E) mutants that are RNAi-resistant 
could be used to try to rescue knockdown of Wrch-1. 
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Figure 4.1 Schematic of dimerization of PDGF ligands and receptors (PDGFR). The 
four PDGF ligands (A,B,C,D) are inactive in their monomeric forms, and are 
required to dimerize to form an active ligand. PDGF receptors consist of two 
isoforms, α and β (upon ligand binding, PDGFR subunits also dimerize in either αα, 
ββ, or αβ combinations.  Once ligand-induced dimerization occurs, 
transphosphorylation and activation of the receptor elicits downstream signaling.  
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Figure 4.2 Schematic of PDGR signaling pathways.  The major signaling pathways 
downstream of PDGFR include PLCγ, STAT3, PI3K, and the Grb2-SOS-Ras-MAPK pathway. 
PDGFR uses these effectors to elicit biological activities such as differentiation, proliferation, 
fibrinogenesis and angiogenesis. 
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4.3 Future Direction 2: Determine if Wrch-1 is necessary for EGFR- and PDGFR-
mediated biological functions.  As stated previously, EGFR is involved in cell proliferation, 
angiogenesis, and adhesion, migration, and invasion (Roskoski, 2004). PDGFR is involved 
in cell proliferation, cellular differentiation, cell growth and development, angiogenesis, and 
fibrogenesis (Andrae et al., 2008). Although much is known about EGFR and PDGFR 
functions, the role of Wrch-1 downstream of either of these receptors is not well 
characterized. In this dissertation, I have shown that both EGFR and PDGFR are upstream 
of Wrch-1 phosphorylation at Y254, and that this modification of Wrch-1 regulates its ability 
to mediate anchorage-independent growth, single cell migration, Matrigel invasion, and 
epithelial cell morphogenesis.   However, it would be useful to determine whether Wrch-1 is 
necessary downstream of EGFR and PDGFR, by knocking down Wrch-1 and determining 
whether cellular responses driven by these receptors are impaired. For example, Wrch-1 
could be knocked down in a cell line that utilizes EGFR signaling for functions such as cell 
proliferation or migration.  Cell proliferation could be measured in control scrambled siRNA 
cells and Wrch-1 knockdown cells using BrdU incorporation or a luminescent cell viability 
assay, whereas migration could be measured using single cell migration assays, scratch 
assays and/or Matrigel invasion assays.   It would also be of interest to determine whether 
Wrch-1 can modulate PDGFR-driven functions such as angiogenesis or fibrogenesis, as 
described above, and if so, whether the phosphodeficient or phosphomimetic mutants can 
rescue the Wrch-1 knockdown.  Based on the data presented in this dissertation, we would 
predict that rescue with phosphodeficient Wrch-1 would restore Wrch-1-driven phenotypes 
such as transformation and migration, whereas phosphomimetic Wrch-1 would not. 
  
If Wrch-1 is necessary for EGFR or PDGFR signaling, it would be useful to try to determine 
where Wrch-1 lies in the EGFR and/or PDGFR signaling pathway.  EGFR, PDGFR and 
Wrch-1 interact with many of the same proteins including Grb2, Cbl, PLCγ, PI3K and Src 
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(Andrae et al., 2008; Chuang et al., 2007; Hynes and Lane, 2005; Shutes et al., 2006).  
However, the exact interplay of these RTKs and Wrch-1 signaling has not been well studied.  
In this dissertation I have shown that EGFR family members and PDGFR can mediate 
tyrosine phosphorylation of Wrch-1. Additionally I have shown that EGFR regulates tyrosine 
phosphorylation of Wrch-1 in a Src-dependent manner.  However, I have not examined how 
Wrch-1 signaling downstream of EGFR and PDGFR phosphorylation interplays with other 
signaling pathways driven by these receptors.  Wrch-1 may act in an uncharacterized linear 
pathway downstream of EGFR and/or PDGFR phosphorylation, or it may function in a 
parallel pathway.  The current evidence presented in this dissertation suggests that, upon 
tyrosine phosphorylation by upstream kinases, Wrch-1 relocalizes to endosomes, where it 
becomes GDP-bound and inactive. Since Wrch-1 expression has been shown to be 
regulated by Wnt signaling and STAT3 activation (Schiavone et al., 2009; Taneyhill and 
Pennica, 2004; Tao et al., 2001), it is easy to speculate that in certain tissue types, or at 
certain points in development, Wrch-1 expression is increased or decreased to fine-tune 
RTK signaling. In support of this notion, Wrch-1 expression has been shown to be altered in 
cancers, but whether it is upregulated or downregulated depends on tumor type (Kirikoshi 
and Katoh, 2002).  Further, either constitutive activation or knockdown of Wrch-1 disrupts 
proper epithelial cell morphogenesis (Brady et al., 2009), suggesting that a proper amount of 
Wrch-1 is required for cell homeostasis.  In order to study precisely what signals control 
Wrch-1 expression, Wrch-1 levels could be measured at the transcript level by RT-PCR after 
stimulation by various Wnts and by increasing STAT3 activity by activating the upstream 
regulator Jak (Janus kinase) (Shuai et al., 1993).  NSC74859, a small molecule inhibitor of 
STAT3 (Siddiquee et al., 2007a; Siddiquee et al., 2007b), could also be used to block the 
induction of Wrch-1 expression that occurs upon increased STAT3 activity. Currently, there 
is no commercially available antibody that can detect endogenous Wrch-1, although several 
attempts have been made by multiple labs and one group has claimed to have such a 
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reagent (Brazier et al., 2009).  Further efforts should be made to generate such an antibody, 
as it would be a valuable tool to explore upstream factors that control Wrch-1 expression.    
 
In order to explore the role of Wrch-1 in modulating RTK signaling, it would be beneficial to 
further examine overlapping effector pathways utilized by EGFR, PDGFR and Wrch-1. In 
this dissertation, I have shown that growth factor stimulation results in the relocalization of 
Wrch-1 from the plasma membrane to internal membranes, and this relocalization results in 
deactivation of Wrch-1.  I have examined activation of two downstream effectors, Pak1 and 
Pyk2. However, activation of other downstream effectors such as PI3K and PLCγ has not 
been examined. PI3K activity downstream of wild-type, constitutively active, and dominant 
negative Wrch-1 can be measured using a FRET based sensor (Ananthanarayanan et al., 
2008) or by measuring phosphorylation states of PI3K substrates.  PLCγ activity 
downstream of Wrch-1 can be assessed using radioactive assays measuring [3H] PIP2.   
 
Furthermore, long-term effects of growth factor stimulation on Wrch-1 phosphorylation, 
localization, activation, and biological outcomes have yet to be examined.  My preliminary 
evidence suggests that Wrch-1 recycles back to the plasma membrane after 
phosphorylation-stimulated relocalization to internal membranes (data not shown), 
suggesting that cycling between a phosphorylated and unphosphorylated state occurs.  
Further studies aimed at addressing the spatiotemporal aspects of Wrch-1 tyrosine 
phosphorylation need to be done.  Here, I have studied Wrch-1 activation status by 
pulldowns using GST-PAK-PBD and by imaging its ability to recruit GFP-PAK-PBD.  Wrch-
1-GTP could also be assessed by using a split GFP complementation assay (Chun et al., 
2007), where GFP is split into two parts, one half that would be associated with either Wrch-
1 and another half associated with an effector such as Pak, which come together to form a 
functional GFP molecule only when Wrch-1 is GTP-bound and therefore capable of effector 
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interaction.  Alternatively, the two halves of GFP could be fused to Wrch-1 itself, and 
engineered so that when the switch I and switch II regions underwent a conformational 
change after GTP binding, the two halves would come together to produce a measurable 
fluorescent signal, which would allow monitoring of Wrch-1 independent of an exogenous 
effector. These probes could provide a dynamically reversible system to study 
spatiotemporal control of Wrch-1 activation in response to growth factor stimulation and 
subsequent tyrosine phosphorylation.  
 
An additional possibility is that Wrch-1 may modulate RTK signaling by altering receptor 
abundance.  For example, Cdc42 has been shown to sequester Cbl and increase 
expression of EGFR.   Cdc42 binds to p85Cool-1 (Cloned-out-of-library)/β-Pix (Pak 
interacting exchange factor), which is a protein that directly associates directly with c-Cbl 
(Wu et al., 2003).  The association of p85Cool-1/β-Pix with c-Cbl prevents EGFR 
ubiquitination by Cbl, therefore reducing destruction of EGFR, resulting in higher EGFR 
expression levels.  Activated Cdc42 was shown to block Cbl from binding to EGFR, which 
increased EGFR expression, sustained ERK activation and increased transformation (Wu et 
al., 2003) (Figure 4.3).  Currently, it is not known whether Wrch-1 interaction with Cbl results 
in the same phenomenon.  First, it would be useful to determine whether Wrch-1 binds to 
p85Cool-1/β-Pix.  On the other hand, Wrch-1 has been shown to bind Cbl in a 
phosphorylation-dependent manner; therefore Wrch-1 could act by directly sequestering 
Cbl, even if Wrch-1 does not bind to p85Cool-1/β-Pix. Next it would be useful to determine 
whether Wrch-1 activation increases EGFR expression levels, EGF-stimulated ERK 
activation, and/or EGFR-dependent transformation.  Further studies aimed at addressing the 
role of Wrch-1 in modulating RTK signaling pathways will give us further insight into overall 
Wrch-1 effector pathways and biological function, and may provide insight on general Rho 
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GTPase regulation with respect to RTK signaling. 
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Figure 4.3 Cdc42 sequesters c-Cbl through binding to p85-Cool-1/β-Pix, resulting in 
decreased degradation and increased abundance of EGFR. Wrch-1 binds to Cbl in a serum-
dependent manner, and may also prevent degradation of EGFR either by binding to p85-
Cool-1/β-Pix or by directly sequestering c-Cbl. 
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4.4 Future Direction 3: Determine how Wrch-1 C-terminal ubiquitination contributes to 
biological function.  Wrch-1 has eight lysines in its C-terminal tail that may be subject to 
mono-ubiquitination (Figure 4.4A).  As previously determined by Anastacia Berzat, a former 
graduate student in our group, Wrch-1 is di-mono-ubiquitinated (Figure 4.4B). Ubiquitination 
involves the covalent attachment of ubiquitin (an 8 kDa protein) to cellular proteins (Hershko 
and Ciechanover, 1998; Pickart and Eddins, 2004).  Ubiquitin is activated in an ATP-
dependent manner by a ubiquitin-activating enzyme known as an enzyme-1 (E1) (Walden et 
al., 2003). The E1 along with a ubiquitin-conjugating enzyme, or E2, and a ubiquitin-protein 
ligase (E3) covalently attaches ubiquitin to a lysine in the substrate protein (Huang et al., 
1999; Pickart and Eddins, 2004).  Ubiquitin is covalently attached to proteins as either a 
single monomer (mono-ubiquitination) or a long chain (polyubiquitination). Polyubiquitination 
usually serves as a signal for degradation by the 26S proteasome (Finley et al., 1994; 
Pickart and Eddins, 2004), whereas mono-ubiquitination regulates protein trafficking, often 
to internal cellular membranes such as endosomes and lysosomes (Figure 4.5) (Finley et 
al., 1994; Haglund and Dikic, 2005). Some Rho family proteins, such as RhoA, Cdc42, and 
Rac1, are polyubiquitinated and degraded in response to the bacterial toxin CHF (Doye et 
al., 2006). Ubiquitination of H-Ras regulates its localization and decreases its signaling to 
the MAPK pathway (Jura et al., 2006).  Wrch-1 is mono-ubiquitinated at one of three lysines, 
K242, K244, or K248, in its C-terminal tail (Figure 4.6A), and this ubiquitination does not 
result in an increase in Wrch-1 degradation (Figure 4.6B). The exact lysine that is 
ubiquitinated cannot be determined because Wrch-1 is still a substrate for ubiquitination 
even after a single or double mutation of each of these lysines (Figure 4.7C), presumably 
due to nonspecific ubiquitination upon loss of the preferred residue.  We hypothesized that 
ubiquitination of Wrch-1 may regulate its biological function.  Consistent with this, we found 
that mutation of the ubiquitinated lysines of Wrch-1 to arginines negatively regulated Wrch-
1-mediated anchorage-independent growth (Figure 4.8).  We hypothesized that, like tyrosine 
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phosphorylation, mono-ubiquitination of Wrch-1 may regulate its subcellular localization and 
subsequent biological function. However, we were unable to detect an alteration in Wrch-1 
localization (Figure 4.9).  
 
Alternatively, Wrch-1 ubiquitination may alter effector binding.  In a recent study, it was 
found that ubiquitin could bind to a subset of SH3 domains (Stamenova et al., 2007).  
Classically, SH3 domains promote protein-protein interactions by binding to PxxP motifs.  
Certain proteins, such as the yeast protein Sla1 and the mammalian protein CIN85, contain 
an SH3 domain capable of binding ubiquitin molecules (He et al., 2007; Stamenova et al., 
2007).  PLCγ, a known effector of Wrch-1, contains an SH3 motif that is highly homologous 
to the SH3 domain of CIN85.  Therefore it is possible that ubiquitination of Wrch-1 could 
modulate binding to effectors, such as PLCγ.  In order to test this hypothesis, co-
immunoprecipitations could be performed with parental Wrch-1 or mutants of Wrch-1 that 
cannot be ubiquitinated, along with known effectors of Wrch-1 that contain an SH3 domain, 
such as PLCγ, Grb2, or Nckβ.  In order to further explore this possibility, activation of 
effectors could be examined in the presence of Wrch-1 that can and cannot be 
ubiquitinated.   
 
It was also discovered that ubiquitin molecules could compete with PxxP motifs for 
interaction with SH3 domains (Stamenova et al., 2007). Wrch-1 contains several PxxP 
motifs in its N-terminal extension that are capable of binding to adaptor proteins such as 
Grb2 and Nckβ.  Binding of the N-terminal PxxP motifs in Wrch-1 to SH3-containing proteins 
is thought to relieve Wrch-1 auto-inhibition by its N-terminal domain. Therefore, 
ubiquitination of Wrch-1 could compete for SH3 binding, thus promoting increased auto-
inhibition of Wrch-1, and negatively regulating Wrch-1 function.  This hypothesis could be 
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addressed in part by using GST-PAK-PBD pulldown assays and GFP-PAK-PBD recruitment 
assays to examine GTP levels in Wrch-1 proteins that can or cannot be ubiquitinated. 
 
Additionally, further investigation into how ubiquitination alters Wrch-1 biological function is 
needed.  To date, I have examined only ubiquitin regulation of Wrch-1-mediated anchorage-
independent growth. However, Wrch-1 is known to contribute to a myriad of other biological 
functions such as adhesion, motility, migration, invasion, osteoclastogenesis, and epithelial 
cell morphogenesis.  To further test the hypothesis that ubiquitination regulates Wrch-1 
biological function, I propose to examine the contribution of mutants of Wrch-1 that can or 
cannot be ubiquitinated to single cell migration, Matrigel invasion, and epithelial cell 
morphogenesis.   
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Figure 4.4 Wrch-1 incorporates ubiquitin molecules. A) The Wrch-1 C-terminus contains 
several potentially ubiquitinated lysines. B) Myc-tagged Wrch-1 or the positive control protein 
SENP2 were expressed in H1299 cells in the presence or absence of HA-tagged ubiquitin.  
All cells were treated with MG132 (proteasome inhibitor) for 6 h.  Myc-tagged proteins were 
immunoprecipitated with anti-myc antibody.  Immunoprecipitates were subjected to SDS-
PAGE and western blot analysis for incorporation of ubiquitin molecules using anti-HA 
antibody. Data courtesy of Anastacia Berzat.  
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Figure 4.5 Process of mono- versus poly-ubiquitination.  A.  Ubiquitin is covalently 
attached to proteins as either a single monomer (mono-ubiquitination) or a long chain 
(polyubiquitination). Polyubiquitination usually serves as a signal for degradation of the 
protein by the 26S proteasome. Mono-ubiquitination of proteins regulates protein 
trafficking to cellular membranes. B.  Ubiquitin is activated in an ATP-dependent manner 
by a ubiquitin-activating enzyme known as an enzyme-1 (E1). The E1 along with a 
ubiquitin-conjugating enzyme, or E2, and a ubiquitin-protein ligase (E3) covalently 
attaches ubiquitin to a lysine in the substrate. protein.  
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Figure 4.6 A) Schematic of multiple K>R mutations made in the C-terminal membrane 
targeting region of Wrch-1. B) Myc-tagged Wrch-1 and Wrch-1 K>R mutants were 
expressed in H1299 cells in the presence of HA-tagged ubiquitin. Myc-tagged proteins 
were immunoprecipitated with anti-myc antibody.  Immunoprecipitates were subjected to 
SDS-PAGE and western blot analysis for incorporation of ubiquitin molecules using anti-
HA antibody.  
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Figure 4.7  A) Schematic of single K>R mutations made in the C-terminal membrane 
targeting domain of Wrch-1. B) Myc-tagged Wrch-1 and Wrch-1 K>R mutants were 
expressed in H1299 cells in the presence of HA-tagged ubiquitin. Myc-tagged proteins 
were immunoprecipitated with anti-myc antibody.  Immunoprecipitates were subjected to 
SDS-PAGE and western blot analysis for incorporation of ubiquitin molecules using anti-
HA antibody.  
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Figure 4.8.   Potentially ubiquitinated lysines cannot be completely substituted with 
arginines to support Wrch-1-mediated anchorage-independent growth. H1299 cells stably 
expressing HA-tagged Wrch-1 were seeded in soft agar and colonies were allowed to 
grow for 21 days.  Viable colonies were stained with MTT and quantified. 
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Figure 4.9. Wrch-1 localization is not altered, despite K>R mutations. GFP-tagged Wrch-
1 and Wrch-1 K>R mutants were expressed in H1299 cells. Cells were visualized live 
using a Zeiss Axioscope.  
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4.5 Future Direction 4:  Determine how Wrch-1 is negatively regulated at endosomes. 
In this dissertation, I have shown that Wrch-1 becomes tyrosine phosphorylated on Y254 in 
response to growth factor stimulation, and that this phosphorylation results in a 
relocalization of Wrch-1 from the plasma membrane to internal membranes.  I have also 
shown that after Wrch-1 relocalizes to internal membranes, it becomes GDP-bound and 
inactive, and that Wrch-1-mediated PAK1 and Pyk2 activation is decreased.  These data 
indicate that Wrch-1 is turned off when relocalized to endosomes, but do not tell us whether 
this is due to increased interaction with an endosomally localized GAP, decreased 
interaction with a plasma membrane-associated GEF, or both.  To date, no GEFs, GAPs or 
GDIs have been shown to regulate Wrch-1, but on the other hand no published studies have 
been specifically designed to probe GEF or GAP regulation of Wrch-1.  It has been shown 
that Wrch-1 does not interact with RhoGDI-1 (Berzat et al., 2006), which is not surprising 
given that RhoGDIs recognize isoprenoid lipids, whereas Wrch-1 is not isoprenylated 
(Berzat et al., 2005b).   
 
Since Wrch-1 is GFP-bound at the plasma membrane but GDP-bound at endosomes, Wrch-
1 may be regulated by an endosomally localized GAP.  There are examples of endosomally 
localized RhoGAPs, including p50RhoGAP, and ARAP1 (Simova et al., 2008; Sirokmany et 
al., 2006).  p50RhoGAP, the first RhoGAP identified, has been shown to localize to 
endosomes, a subcellular localization that is mediated by its Sec-14-like domain (Sirokmany 
et al., 2006).  ARAP1 has both Arf and Rho GAP domains, and has been shown to regulate 
trafficking and degradation of EGFR (Daniele et al., 2008; Yoon et al., 2008).  Based on the 
localization of these RhoGAPs, p50RhoGAP and ARAP1 are good candidates for down-
regulating Wrch-1 activity at endosomes. To test whether these GAPs are capable of 
regulating Wrch-1 nucleotide binding, I could perform in vitro GTPase assays as described 
in Shutes et al (Shutes et al., 2006).  Additionally, co-immunoprecipitations using Wrch-1 
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and Wrch-1 phosphorylation mutants could be performed to determine whether Wrch-1 
interacts with these GAPs in a localization-dependent manner.   Finally, I could knock them 
down and then determine if endosomally localized Wrch-1 remains GTP-bound in their 
absence.  
 
Although p50RhoGAP and ARAP1 are good candidates for regulation of Wrch-1 activity at 
endosomes, there could be other unidentified endosomally localized GAPs that could be 
regulating Wrch-1 instead of or in addition to p50RhoGAP and/or ARAP1.  To identify such 
candidate GAPs, mass spec analysis of proteins that co-immunoprecipitate with mutationally 
activated Wrch-1(Q107L) but not with chronically GDP-bound Wrch-1(T63N) could be 
utilized.  To determine which GAPs interact with Wrch-1 at the endosomes versus the 
plasma membrane, Wrch-1 phosphorylation mutants (Y254F and Y254E) could be used to 
identify proteins that bind Wrch-1 at the plasma membrane and internal membranes, 
respectively.    
 
Many other interesting questions remain.  For example, it will also be interesting to 
determine the identity of the phosphatase(s) that restore Wrch-1 to the plasma membrane, 
to more precisely characterize the stoichiometry of the pools of Wrch-1 that are localized to 
different sites in the cell, and to define the roles of these different pools in specific Wrch-1-
mediated biological functions. 
 
In this dissertation, I have tried to emphasize how Wrch-1 C-terminal tyrosine 
phosphorylation downstream of growth factor stimulation regulates Wrch-1 localization and 
function.  More work is needed to further define the role of Wrch-1 phosphorylation and its 
interplay with other RTK signaling pathways. Additionally, more work is required to 
characterize how other post-translational modifications, such as ubiquitin, regulate Wrch-1 
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function.  Further investigation into how post-translational modifications regulate Wrch-1 will 
provide insight on how Wrch-1 is regulated in normal and cancer cells, and may shed light 
on novel modes of Rho protein regulation.  
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